Podcasts about Coa

En tant qu'entrepreneur ou cadre dirigeant, vous suivez vos indicateurs de performance, vous révisez vos plans et vous anticipez les risques de votre entreprise. Qu'en est-il de votre corps ?Notre invité, Paul Dupuy, a construit sa carrière loin de la médecine : la publicité sur Internet, puis la PropTech. En 2020, un check-up préventif réalisé chez un médecin change sa façon de vivre et de travailler, il cofonde ainsi Zoï fin 2021 pour démocratiser la médecine préventive.Le principe ? Un check-up approfondi suivi de douze mois d'accompagnement, pour comprendre mieux connaître son corps, identifier ses zones de risque et construire un plan d'action santé personnalisé. Cinq ans plus tard, plus de 5 000 check-ups réalisés, 80 experts médicaux et un centre de 18 suites en plein Paris, il partage son expérience et dévoile les mauvaises habitudes des dirigeants en matière de santé.Au programme de cet épisode : Comment on peut se croire en forme et accumuler les mauvaises habitudes sans le voir  La différence réelle entre le dépistage classique et la prévention personnalisée Ce que des milliers de bilans révèlent sur des gens qui se croyaient en pleine forme Pourquoi la santé du dirigeant reste taboue dans les réseaux d'entrepreneurs et les opérations de cession Le cas d'un dirigeant qui a fait un check-up juste après avoir vendu son entreprise, et ce qu'on y a trouvé Vous consultez la synthèse de votre portefeuille tous les mois. Votre corps, lui, n'a pas de tableau de bord. Quarante minutes pour comprendre pourquoi c'est un problème.  Ressources complémentaires Prévoyance du dirigeant d'entreprise : sécuriser son entreprise, protéger sa famille, organiser sa transmission : https://sapians.com/blog/prevoyance-dirigeantVente d'entreprise : comment vivre de son capital sans l'épuiser après la cession : https://sapians.com/blog/vivre-de-son-capital-apres-cession-entrepriseLes étapes de la cession d'entreprise : bonnes pratiques et pièges à éviter : https://sapians.com/blog/cession-entrepriseComparatif : quelle solution de gestion de patrimoine choisir quand on dirige une entreprise ? : https://sapians.com/blog/solutions-gestion-patrimoine-entrepreneur ------------------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

This presentation clarifies how ketone bodies function as a vital alternative fuel for the human body. Produced within the liver, these compounds are synthesized from acetyl-CoA molecules that originate during the breakdown of fatty acids. Once released into the bloodstream, they supply necessary energy to various areas, including the brain and skeletal muscles. This metabolic process becomes especially critical during periods of fasting when glucose levels are low. Ultimately, the source emphasizes the importance of understanding how these substances sustain peripheral tissues throughout the body.

En tant qu'entrepreneur ou cadre dirigeant, vous avez probablement tout structuré dans l'entreprise et délégué aux bonnes personnes de votre équipe. Qu'en est-il de votre vie personnelle ?Vie perso du dirigeant, notre nouvelle série, consacre quatre épisodes à cet angle mort : le quotidien et la charge mentale, la santé, la structuration juridique de la vie privée. Notre première invitée, Rebecca Fischer-Bensoussan, a passé quinze ans dans la finance, jusqu'à faire partie du comité de direction de Groupama Asset Management à 34 ans. Mais en 2022, elle a pivoté radicalement pour cofonder Yolo avec Camille Agon.  Le principe ? Un collectif d'alliées, une communauté qui prend en charge la vie réelle des dirigeants et des salariés. Quatre ans plus tard, une cinquantaine d'entreprises clientes dont une quinzaine de groupes du CAC 40 et plus de 30 000 demandes traitées.  Dans cet épisode, Aurore Perrin aborde avec elle : pourquoi déléguer sa vie pro est banal quand déléguer sa vie perso reste un aveu d'échec ce que des centaines d'accompagnements révèlent des habitudes des dirigeants le coût réel de la charge mentale pour une entreprise, chiffres à l'appui pourquoi les femmes dirigeantes détiennent souvent de l'equity et rien d'autre ses propres arbitrages d'organisation, ceux qu'elle assume et ce sur quoi elle a lâché Une heure sur ce qui se joue en dehors du bureau, et qui impacte pourtant de ce qui s'y passe. Dans le prochain épisode, nous poursuivons la série avec un autre pilier de la vie du dirigeant : sa santé.Ressources complémentaires Divorce d'un entrepreneur : guide de protection du patrimoine et de l'entreprise https://sapians.com/blog/divorce-entrepreneur Prévoyance du dirigeant d'entreprise : sécuriser son entreprise, protéger sa famille https://sapians.com/blog/prevoyance-dirigeant Quelle solution de gestion de patrimoine choisir quand on dirige une entreprise ? https://sapians.com/blog/solutions-gestion-patrimoine-entrepreneur Pour quelles raisons investir dans une assurance-vie ? https://sapians.com/blog/pourquoi-investir-assurance-vie-avantages-inconvenients ------------------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

You've probably seen ocimene on a label and moved right past it. What the hell is it, and what does it bring to your flower?This week, we're getting into another terp, talking through ocimene's woody, sweet, herbal notes and why plants produce these compounds in the first place. Because apparently plants have a whole lot of shit going on, and making your weed smell good is only part of this conversation.Of course, we take a few turns along the way. We're comparing grinders, talking about our very different experiences with flower and carts, and sharing those moments when getting elevated turns into being way too focused on one sensation. We also question some of the claims attached to ocimene—because seeing “uplifting” next to a terpene doesn't tell you how that whole strain is going to feel.The conversation keeps coming back to knowing what you're consuming. Look past the strain name, check the terpene profile, and pay attention to your own experience. There's a lot more to your flower than the THC number on the front.In this episode:00:24 — Getting familiar with ocimene and where we've noticed it01:40 — Woody, sweet, floral: talking aroma and terpene families02:42 — Cis, trans, and questions we still have about the chemistry03:38 — Herbs, fruit, and why plants produce terpenes05:40 — Plant defenses and calling in backup against pests07:05 — Decongestant claims and our personal experiences with congestion09:06 — Grinders, flower mills, kief, and the quality of your grind12:02 — Comparing our experiences with THC, flower, and distillate carts14:50 — Cartridge dosing and checking the certificate of analysis (COA)16:50 — Intentional consumption and the stoner stereotype21:12 — Does “uplifting” tell the whole story?22:37 — Mixing strains—and somehow, ketchup on mac and cheese23:54 — Looking beyond strain names to what's actually in the flowerHave you noticed ocimene in any of your favorite strains? And are you checking the terps when you shop, or still going off the name? Drop your experiences and questions in the comments.Check out the links below for our favorite gear and goodies. We'll catch you next time.Find everything in one place here:

The provided text describes the central role of acetyl CoA as a vital metabolic crossroads where various nutrients converge. While commonly associated with the breakdown of glucose and pyruvate, this molecule is also generated through the oxidation of fatty acids and the processing of amino acids. Furthermore, the material highlights that ethanol contributes to this pool by transitioning through intermediate stages like acetate. Even ketone bodies serve as a source when they are processed within tissues outside of the liver. Ultimately, these diverse pathways illustrate how fats, proteins, carbohydrates, and alcohol all transform into a shared chemical intermediate to fuel the body.

Quinze ou vingt ans à tout réinvestir dans votre entreprise, maintenir des salaires raisonnables, parfois des dividendes... Et au final, un manque de liquidités pour vos projets personnels ? C'est un cas que Paul Bougnoux voit revenir très souvent : un dirigeant ou une dirigeante de 50 ans, dont la résidence principale est encore financée à crédit, qui n'a rien mis de côté, et dont le patrimoine tient presque entièrement dans une société qu'il ne peut monétiser qu'en la vendant. Pourtant il existe parfois une autre voie que la cession à des tiers : l'Owner Buy Out ou la vente à soi-même. Paul Bougnoux est fondateur et président de Largillière Finance, banque d'affaires indépendante qui a fêté ses vingt ans. Une cinquantaine de professionnels à Paris, des bureaux à Nantes, Lyon, Bordeaux, Genève et Bruxelles, des transactions comprises entre 20 et 300 millions d'euros, et deux tiers des opérations réalisées en région. À titre personnel, plus de 400 transactions menées. Dans ce Just Tips, il déroule avec Aurore Perrin le mécanisme de l'OBO et tout ce qui gravite autour : Qu'est-ce que l'OBO ? Que se passe-t-il concrètement quand un dirigeant se vend sa société à lui-même, et d'où vient l'argent qu'il encaisse ? Pourquoi la dette via l'OBO permet un risque mieux encadré qu'il n'y paraît  Ce que change réellement avec l'arrivée d'un fonds minoritaire au capital Pourquoi les managers ont tout intérêt à payer leurs actions plutôt qu'à les recevoir L'état réel des valorisations, et comment l'IA est entrain de changer le secteur ? Écoutez cet épisode pour comprendre cette opération avantageuse que beaucoup de dirigeants n'envisagent jamais.  Ressources complémentaires :Faire un exit partiel sans perte de contrôle avec l'OBO : https://sapians.com/blog/obo-owner-buy-out Du build-up à l'OBO : 6 leviers de croissance et de liquidité pour les dirigeants de PME : https://sapians.com/blog/leviers-croissance-cession-dirigeant Valorisation d'entreprise : comment maximiser le prix net de cession ? : https://sapians.com/blog/valorisation-entreprise-cession Transmettre son patrimoine par sa holding : le guide complet : https://sapians.com/blog/holding-transmission-patrimoine Cession d'entreprise : pourquoi associer banque d'affaires et gestionnaire de fortune ? : https://sapians.com/blog/banque-d-affaires-vs-gestionnaire-de-fortune-cession-entreprise -----------------------Attention : Ceci est une communication publicitaire. Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians. SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

He sells vapes with no nicotine. Every ad platform, payment processor, and carrier treats him like Big Tobacco anyway.Conrad Kurth founded Cyclone Pods in 2018 after watching every friend he had get hooked on Juul. Eight years later the brand has grown every year with a 60 percent repeat customer rate, no paid ads, no Shopify Payments, and no USPS. This is what selling on hard mode actually looks like.What you'll learn:Why a product with no addictive ingredient still gets a 60% repeat rateWhere a new customer really comes from when Meta, Google, and TikTok won't run your adsWhy "alternative advertising" on age-restricted sites sent traffic that never convertedThe Sunday morning Shopify Payments shut off with no warning, and the standalone store he keeps ready for next timeHow UPS and FedEx agreed to ship after seeing lab data, and why USPS never willWhether publishing third-party lab results helps SEO (his honest answer: he can't prove it)Why Wisconsin only allows vapes from Philip Morris, Altria, and ReynoldsThe Focus Pouch story: caffeine plus lion's mane, reishi, and cordyceps, two years before caffeine pouches were a categoryVapes for dogs, the leaking device that got pulled, and what he'd tell his 2018 selfHis advice for anyone selling a restricted product: ignore the ad people, do the legwork yourselfGuest: Conrad Kurth, founder and CEO of Cyclone Pods, a nicotine-free vape and nootropic pouch brand based in Santa Monica, California. Former software engineer.Show Links:Cyclone Pods: https://cyclonepods.comEmail Conrad: conrad@cyclonepods.comSPONSORSSwym - Wishlists, Back in Stock alerts, & moregetswym.com/kurtCleverific - Smart order editing for Shopifycleverific.com/unofficialZipify - Build high-converting sales funnelszipify.com/KURTWORK WITH KURTApply for Shopify Helpethercycle.com/applySee Our Resultsethercycle.com/workFree Newsletterkurtelster.comThe Unofficial Shopify Podcast is hosted by Kurt Elster and explores the stories behind successful Shopify stores. Get actionable insights, practical strategies, and proven tactics from entrepreneurs who've built thriving ecommerce businesses.

Quand on parle de dette émergente, on pense d'abord aux emprunts des États. Sidney Oury, lui, fait tout autre chose : il prête aux entreprises. Il investit dans les obligations de sociétés installées dans des pays émergents comme le Brésil, le Mexique, la Colombie ou l'Argentine.C'est ce qu'on appelle la dette corporate émergente, et c'est un métier bien à part.Le principe ? Une entreprise n'est presque jamais considérée comme plus fiable que le pays où elle opère : une société bien gérée doit donc payer un taux d'intérêt élevé pour emprunter, en grande partie à cause de la note de son pays. Une entreprise comparable installée dans un pays riche paierait souvent deux fois moins. La conviction de Sidney Oury est qu'une partie de cet écart tient à l'étiquette du pays, pas à la solidité réelle de l'entreprise. Il appelle ce phénomène l'effet code postal.Concrètement, pour l'investisseur, prêter à ces entreprises en achetant leurs obligations, c'est toucher des intérêts réguliers, plus élevés que sur des sociétés tout aussi solides des pays riches. C'est là que réside l'intérêt de la stratégie : les fonds d'IVO visent de l'ordre de 7 % par an en euros. La contrepartie, c'est le risque qu'une entreprise ne rembourse pas, d'où l'importance de la sélection.En 2012, il quitte Merrill Lynch pour co-fonder IVO Capital Partners avec Michael Israel et construire une gestion autour de cette idée. Quatorze ans plus tard, IVO gère près de 3 milliards d'euros. Dans cet épisode, Aurore Perrin explore avec lui :      Ce qu'est concrètement la dette corporate émergente, et pourquoi elle n'a rien à voir avec la dette des États      Pourquoi une entreprise solide peut être obligée de payer un taux d'intérêt aussi élevé      Comment IVO choisit ses entreprises, et pourquoi l'investisseur n'est pas exposé aux monnaies locales      Ce que les grandes crises (2018, 2022, Covid) changent pour un investisseur      Les trois critères de Sidney pour reconnaître un bon fonds Près de 45 minutes pour comprendre un placement concret et exigeant, avec son potentiel de rendement comme avec les risques propres aux marchés émergents. Ressources complémentaires :Dette et obligations d'État : quelles stratégies sur les marchés obligataires en 2025 ? https://sapians.com/blog/focus-marches-obligations-etat-entreprise Dette privée en Europe et aux États-Unis : quels fonds privilégier ? https://sapians.com/blog/investir-dette-privee Biais domestique : votre patrimoine dépend trop de la France ? Comment diversifier à l'étranger https://sapians.com/blog/diversifier-patrimoine-hors-de-france Décorrélation des actifs : la clé d'un portefeuille résilient face aux crises https://sapians.com/blog/decorrelation-actifsPodcast « Focus Fonds » : Laurent Calvet présente Tikehau Capital https://sapians.com/blog/podcast-just-focus-tikehau-capital -----------------------Attention : Ceci est une communication publicitaire. Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians. SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

During a period of fasting, the liver serves as a vital metabolic hub by generating alternative fuel sources for the rest of the body. To accomplish this, the organ utilizes fatty acids to produce a surplus of acetyl-CoA, which is then converted into ketone bodies. This process, known as ketogenesis, ensures that peripheral tissues have access to energy when food intake is restricted. Furthermore, the liver maintains systemic stability by simultaneously releasing glucose into the bloodstream. These combined efforts highlight the liver's essential role in managing energy distribution and metabolic adaptation during nutrient scarcity.

Send us Fan MailThat little QR code on your cannabis jar can be a shortcut to clarity or a trap you scroll past while chasing the biggest THC number. We're breaking down how to read a cannabis Certificate of Analysis (COA) so it stops feeling like fine print and starts acting like what it is: a third-party lab report that can help you make safer, smarter choices for flower, concentrates, and especially edibles.Find a sample COA on the website. If you've got a COA that's confusing you, listen along, pull up your own lab report, and read it with us. Subscribe, share this with a friend who only shops by THC, and leave a review so more people learn how to use COAs with confidence.The map you need to start making great edibles in easy, digestible lessons. Sign up for Free. I'm taking clients for 1-on-1 Cannabis Education Sessions, see more here and book your free exploratory call. Support the show Visit the website for full show notes, free dosing calculator, quiz, recipes and more. 

Un dirigeant de PME ne vend son entreprise qu'une fois dans sa vie. Ses parents ne l'ont pas fait, ses voisins non plus : le jour où il décide de céder le projet d'une vie, il découvre un jeu dont il ne connaît aucune règle. C'est précisément ce moment que décrypte cet épisode.Arnaud Picaudé est associé fondateur de Cairus, une banque d'affaires qui a fait le pari inverse des grands cabinets parisiens : dix-sept bureaux en région, un maillage au plus près des dirigeants, et une spécialité sur les PME valorisées entre 1 et 10 millions d'euros ; ce tissu entrepreneurial que le M&A traditionnel laisse souvent de côté.Passé par le réseau bancaire du Grand Est puis par Bpifrance, il accompagne aujourd'hui des centaines de cédants.Dans cet épisode, nous abordons :à partir de quel montant un conseil M&A change vraiment la donne, et quand s'en passer ;ce qu'apporte une banque d'affaires qu'un dirigeant ou son expert-comptable ne peuvent pas faire seuls ;comment se construit une valorisation stratégique, bien au-delà des comptes ;les trois questions à poser pour choisir le bon conseil ;les cinq chantiers à ouvrir dès aujourd'hui pour rendre son entreprise désirable.-----------------------Ressources complémentaires Cession de PME : avantages et limites d'une banque d'affaires (https://sapians.com/blog/cession-pme-avantages-limites-banque-d-affaires)PME et M&A : les meilleures banques d'affaires en France (https://sapians.com/blog/classement-banques-d-affaires-pme)Les étapes de la cession d'entreprise : bonnes pratiques et pièges à éviter (https://sapians.com/blog/cession-entreprise)Réussir sa cession : les rôles de la banque d'affaires et du gestionnaire de fortune (https://sapians.com/blog/banque-d-affaires-vs-gestionnaire-de-fortune-cession-entreprise) -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Er is er een jarig, hoera, hoera en dat is Bassie Paternotte (50!). Toch gewoon een Nare Jongens Podcast, met een terugblik op 1 september 1976. En natuurlijk het grote nieuws van 1 september 2026: ze zijn er uit, de kneuzen van het minderheidskabinet. En hij is er uit, de hoofdredacteur van Ongehoord Nederland. Plus: Tom de Nooijer schiet terug, deze keer niet met een Kalashnikov, maar met COA-feiten. Plus: veel meer. Extra's ook ontvangen: https://petjeaf.com/narejongens

Thibault Lamarque est le fondateur de Castalie, entreprise pionnière de l'eau microfiltrée en France, lancée en 2011. A 30 ans, après un début de carrière en finance (notamment chez Veolia), il a développé un modèle par abonnement qui a permis de déployer plus de 7 500 fontaines.La croissance de Castalie s'est structurée autour de leviers successifs : fonds propres, friends & family, fonds en equity, puis de la dette avec Pictet afin de financer l'accélération sans dilution.Dans cet épisode, Thibault revient sur sa stratégie de financement, ses arbitrages patrimoniaux et sa vision d'investisseur engagé. Découvrez : Son retour d'expérience sur les différences sources de financement dont il a bénéficiéPourquoi il a choisi un industriel comme investisseur et comment gérer la pression de sortie des fonds face à sa vision long terme.Son recours récent à la dette avec Pictet, pour financer le développement et le CapEx sans dilution, et refinancer les infrastructures existantes.Sa stratégie d'investissement 100% depuis son cash-out en 2020 : pourquoi, selon lui, l'investissement “impact” est souvent moins risqué qu'on ne l'imagine et pourquoi il refuse systématiquement d'investir dans la tech "pure".Son accompagnement concret de startups comme FruityCorp. Benjamin Dubois (son fondateur) nous rejoint en fin d'épisode pour partager comment Thibault l'a guidé sur le timing de levée et la structuration financière.Bonne écoute !Pour aller plus loin sur les sujets abordés : Business Angel : guide complet pour investir dans une start-up https://sapians.com/blog/business-angel Le cash-out : définition, fonctionnement et investissement https://sapians.com/blog/cash-out-definition-fonctionnement-avantagesInvestir dans un fonds de dette privée ? Définition et fonctionnement https://sapians.com/blog/focus-dette-priveeLe Carried Interest en Private Equity : Définition, Fonctionnement, Fiscalité & Conseils d'Experts https://sapians.com/blog/carried-interestGestion Passive vs Gestion Active : comment mettre en place sa stratégie d'investissement ? https://sapians.com/blog/gestion-passive-vs-gestion-active-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Guillaume de Kergariou est le fondateur de NeedHelp et Octorenov. Ancien banquier en M&A devenu entrepreneur, il a créé NeedHelp, l'a vendue à un grand groupe coté… avant de la racheter quatre ans plus tard en MBO pour retrouver sa liberté, tout en construisant parallèlement une vie d'investisseur très active.Dans cet épisode, Guillaume revient sur son parcours, ses arbitrages et sa vision à long terme dans l'entrepreneuriat comme dans l'investissement :Ce qui l'a poussé à quitter le M&A pour se lancer dans une marketplace de services à domicile.Les défis invisibles derrière la construction d'une marketplace rentable et scalable.Les enjeux humains et stratégiques d'une cession à un industriel lorsqu'on a bâti son entreprise de zéro. Et comment il a procédé pour racheter sa propre société.Sa stratégie d'investissement et la manière dont il a dû repenser ses convictions face aux réalités du non-coté.Bonne écoute !Pour aller plus loin sur les sujets abordés : Business Angel : guide complet pour investir dans une start-up https://sapians.com/blog/business-angel Le cash-out : définition, fonctionnement et investissement https://sapians.com/blog/cash-out-definition-fonctionnement-avantagesLes étapes de la cession d'entreprise : bonnes pratiques et pièges à éviter https://sapians.com/blog/cession-entreprise Qu'est ce que l'apport-cession en immobilier ? (150-0 B ter CGI) https://sapians.com/blog/apport-cession-reinvestissement-immobilierGestion Passive vs Gestion Active : comment mettre en place sa stratégie d'investissement ? https://sapians.com/blog/gestion-passive-vs-gestion-active-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Robin Padilla and Imee Marcos take turns in defending Sara Duterte and grilling a COA witness.

Depuis le 1er juillet, les plateformes crypto qui n'ont pas obtenu l'agrément européen MiCA voient leurs opérations très fortement limitées. Résultat : certains détenteurs de cryptomonnaies se sont réveillés avec des actifs qu'ils ne pouvaient plus vendre contre des euros.Edwin de Trédern, notre invité, en a fait l'expérience lui-même ayant réalisé début juillet qu'une partie de l'argent qu'il avait placé en crypto était maintenant indisponible, car bloqué sur une plateforme non agréée. Il a dû transférer en urgence ses cryptoactifs pour pouvoir les récupérer.Cofondateur et président d'AlphaCap Digital Assets, Edwin accompagne des gestionnaires de patrimoine qui proposent des solutions crypto à leurs clients. Avec l'entrée en vigueur de la réglementation européenne MiCA, son métier a changé de nature : il porte désormais une responsabilité directe sur l'adéquation des recommandations données à chaque client. Dans cet épisode, nous abordons : Que faire si votre distributeur crypto n'a pas obtenu l'agrément MiCA, et pourquoi il ne faut pas trop attendre pour transférer ses actifs Comment vérifier en deux minutes qu'un acteur crypto est réellement régulé (et éviter les faux sites) Garde institutionnelle ou cold wallet : quelle solution pour sécuriser ses cryptoactifs selon la taille de son patrimoine Quelle place raisonnable donner à la crypto dans une allocation globale, et pourquoi elle reste un satellite Le démembrement de propriété appliqué aux cryptomonnaies : une technique de transmission méconnue mais redoutablement efficace Un épisode concret pour tous ceux qui détiennent déjà des cryptoactifs, ou qui se demandent comment les intégrer intelligemment à leur patrimoine. -----------------------Ressources complémentaires Comment optimiser la fiscalité de votre patrimoine (héritage, succession, transmission) ? (https://sapians.com/blog/optimiser-fiscalite-heritage-succession) Comment utiliser sa holding pour transmettre son patrimoine ? (https://sapians.com/blog/holding-transmission-patrimoine) Projet de Loi de Finances 2026 : ce qui change pour votre patrimoine (https://sapians.com/blog/loi-de-finances-plf-2026-patrimoine-fiscalite) -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

NEWS: Pag-IBIG once again earns COA recognition | August 1, 2026Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribe Visit our website at https://www.manilatimes.net Follow us: Facebook - https://tmt.ph/facebook Instagram - https://tmt.ph/instagram Twitter - https://tmt.ph/twitter DailyMotion - https://tmt.ph/dailymotion Subscribe to our Digital Edition - https://tmt.ph/digital Check out our Podcasts: Spotify - https://tmt.ph/spotify Apple Podcasts - https://tmt.ph/applepodcasts Amazon Music - https://tmt.ph/amazonmusic Deezer: https://tmt.ph/deezer Stitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes#KeepUpWithTheTimes Hosted on Acast. See acast.com/privacy for more information.

Le 1er juillet 2026, la crypto a changé de statut en France. Sur plus de 1 200 acteurs enregistrés en Europe avant MiCA, moins de 300 ont décroché l'agrément, et à peine une vingtaine en France. Fin de la récréation : un tri historique a été effectué et sépare désormais les acteurs régulés des autres. Pour comprendre ce que ça change vraiment, Aurore Perrin croise deux regards. Celui du droit, avec Clarisse Castellani,  Responsable Juridique chez Mata Capital, qui a piloté un dossier d'agrément et sait précisément ce qu'un régulateur exige aujourd'hui. Et celui du marché, avec François Laviale, gérant crypto chez Alphacap Digital Assets, un acteur agréé qui voit de l'intérieur l'impact de cette régulation sur l'écosystème. Dans cet épisode, vous découvrirez : Ce que MiCA a réellement changé au 1er juillet 2026, et pourquoi tant d'acteurs ont disparu Ce que l'AMF exige concrètement pour délivrer un agrément (fonds propres, ségrégation des actifs, honorabilité des dirigeants) Pourquoi la conformité est devenue un avantage concurrentiel, pas seulement une contrainte L'affaire USDT, la directive fiscale DAC8 et ce qu'elles impliquent pour les détenteurs de crypto Les zones grises que MiCA ne couvre pas encore : DeFi, tokenisation, NFT Comment reconnaître, en pratique, un acteur crypto sérieux 40 minutes pour comprendre ce que « crypto sérieuse » veut vraiment dire. Ressources complémentaires Épisode Focus Fonds : François Laviale présente Alphacap Digital Assets — https://sapians.com/blog/podcast-just-focus-alphacap-digital-assetsPLF 2026 : ce qui change pour votre patrimoine (et vos actifs numériques) — https://sapians.com/blog/loi-de-finances-plf-2026-patrimoine-fiscaliteRéaliser un audit patrimonial : pourquoi ? comment ? — https://sapians.com/blog/audit-patrimonial------------------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Juin 2026 a signé le pire mois de sorties jamais enregistré sur les ETF Bitcoin, et pourtant JP Morgan accepte désormais le Bitcoin en collatéral et les plus grandes banques du monde travaillent en coulisses sur les actifs numériques. Le prix baisse quand l'adoption institutionnelle accélère. Comment lire un marché qui envoie des messages aussi opposés ? Pour y voir clair, Aurore Perrin reçoit François Laviale, gérant crypto chez Alphacap Digital Assets. Cela fait plus de dix ans qu'il évolue dans cet écosystème, à une époque où défendre le Bitcoin vous faisait passer pour un complotiste. Son métier : lire ce marché au-delà du bruit médiatique. Dans cet épisode, on aborde : La photo du marché à l'été 2026 : où en est-on vraiment dans le cycle Pourquoi la baisse est conjoncturelle (Iran, baleines, effet SpaceX) et non structurelle Bitcoin en trésorerie d'entreprise : allocation intelligente ou effet de levier déguisé La thèse de la couverture contre la dévaluation monétaire, de Bretton Woods à Larry Fink Comment construire une allocation crypto raisonnable pour un investisseur patrimonial L'impact réel (et indirect) de l'IA sur le marché Un échange dense et pédagogique pour comprendre ce qui se joue vraiment derrière les cours. Le seul indicateur à surveiller ? Ce n'est pas le prix. François vous explique pourquoi. -----------------------Ressources complémentaires Gérer son patrimoine : comment faire ? (https://sapians.com/blog/gerer-son-patrimoine) Investir son argent : comment faire les bons choix ? (https://sapians.com/blog/bien-investir-son-argent-faire-les-bons-choix-investissement) Quel ETF choisir pour une allocation performante et résiliente ? (https://sapians.com/blog/quel-etf-choisir) Le fonctionnement d'un ETF (https://sapians.com/blog/fonctionnement-etf) Crédit Lombard : définition, exemples et conditions (https://sapians.com/blog/credit-lombard) -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

In EW Politiek Vandaag duikt host Sam Verbeek samen met politiek redacteur Victor Pak in het Nederlandse asieldebat. Aanleiding is de steekpartij in Ter Apel, maar het gesprek gaat verder: van de asielcrisis en opvangproblematiek tot de spreidingswet, het COA, Europese migratieregels, de asielinstroom en de politieke strijd in Den Haag. Waarom beloven kabinetten al decennia grip op asiel, maar blijft een structurele oplossing uit? En kan het nieuwe kabinet het vastgelopen asieldossier eindelijk doorbreken?EW Politiek Vandaag is je korte update over Nederlandse politiek: wat doet het laatste (geo)politieke nieuws met de bloeddruk op het Binnenhof? Victor Pak (politiek verslaggever) en Sam Verbeek (online redacteur) duiden twee keer per week de impact van Tweede Kamer-debatten, verkiezingen, kabinet en internationale ontwikkelingen (EU, VS, China). Elke maandag en donderdag in je podcastapp én op YouTube.Wil je reageren? Stuur dan je vraag of opmerking naar podcast@ewmagazine.nl. Deel de podcast met vrienden en kennissen en laat een review achter.

V for Valentine bestaat bijna 6 jaar! Boris en Robert bespreken microdosen met psychedelica, een WOO-verzoek naar COA-opvanglocaties, het Nederlandse slavernijverleden en de vraag of "het recht op iets" filosofisch bestaat. Ook: hoe slachtofferschap tegenwoordig verdeeld wordt, de doorgedrukte Chat Control wetgeving, verkeerd gemeten inflatie en de vraag of Lindsey Graham vermoord is.00:01:15 6 jaar V4V00:02:45 Microdosen psychedelica00:09:07 WOO-verzoek COA00:15:00 Bestaat 'het recht op iets'?00:19:00 Slavernijverleden Nederland00:27:07 Slachtofferschap verdeeld00:38:15 Chat Control erdoorheen00:48:22 Inflatie verkeerd gemeten00:53:00 Lindsey Graham vermoord?01:00:00 Xtra previewXtra-leden: luister het volledige gesprek zonder onderbrekingen via https://vforvalentine.com

Guerre en Ukraine, Covid, droits de douane, conflit au Moyen-Orient : les crises se suivent et ne se ressemblent jamais. Mais si chacune frappe différemment vos classes d'actifs, existe-t-il une façon de construire un portefeuille qui encaisse les chocs sans s'effondrer en bloc ? Dans ce nouvel épisode de Just Tips, Aurore Perrin reçoit Étienne de Saint-Germain, responsable de l'offre et des services chez Sapians, pour parler de décorrélation : un principe encore méconnu, que la plupart des investisseurs n'explorent jamais au-delà de la simple diversification, et qui fait pourtant toute la différence quand les marchés tanguent. -----------------------Au programme de cet épisode : Pourquoi « ne pas mettre tous ses œufs dans le même panier » ne suffit pas à se protéger des crises La matrice de corrélation que Sapians utilise pour construire ses portefeuilles, et ce qu'elle révèle sur le private equity, l'immobilier ou les obligations Le vrai niveau de corrélation entre le LBO et les marchés actions Pourquoi le private equity secondaire décorrèle mieux qu'un fonds primaire Le modèle des endowments universitaires américains (Harvard, Yale, MIT), et ce qu'il inspire chez Sapians Un épisode pour comprendre pourquoi la vraie expertise n'est pas de prédire la prochaine crise, mais de construire une allocation qui n'a pas besoin de la prédire pour y survivre. -----------------------*Épisode enregistré fin mars 2026 : certains éléments de contexte ont pu évoluer depuis.* -----------------------Ressources complémentaires : Investir en private equity secondaire ? Fonctionnement, avantages, stratégie (https://sapians.com/blog/private-equity-secondaire) Actifs réels : pourquoi et comment investir ? (https://sapians.com/blog/investir-actifs-reels) Rachat avec effet de levier : tout savoir du LBO (https://sapians.com/blog/definition-lbo) Guide complet pour investir en dette privée (https://sapians.com/blog/investir-dette-privee) -----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

On this episode, Jared pulls back the curtain on what supplement quality certifications really mean. What does third-party tested actually tell you? Is cGMP certification enough? How does NSF certification differ from NSF Certified for Sport? And should you avoid ingredients sourced from China or India? Jared explains how reputable manufacturers verify ingredient identity, potency, purity, and consistency through multiple layers of testing, annual audits, and finished product verification. He also shares real-world examples from Vitality Nutrition, including why certain products have been temporarily out of stock because they failed quality standards or were delayed in customs. If you've ever wondered how to separate meaningful quality standards from marketing buzzwords, this episode will help you become a more informed and confident supplement shopper.Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.This podcast is produced by DrTalks.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drtalks.com/podcast-service/⁠

Un bon fonds de private equity double la mise en dix ans. C'est le repère qu'utilise Pierre-Marie de Forville.Un investisseur qui s'arrête à ce chiffre peut pourtant se retrouver, dans les faits, avec un TRI personnel deux fois plus faible que celui affiché par le fonds. La faute à des indicateurs mal compris, et à un métier que presque personne n'anticipe : le cash management.Pierre-Marie de Forville est cofondateur et président d'iVesta Family Office, l'un des plus importants family offices indépendants français, et associé de Sapians. Avec son équipe, il passe une partie de son temps à analyser des data rooms institutionnelles de fonds de private equity : environ 300 par an, pour n'en retenir qu'une quinzaine.Dans cet épisode, il partage sa grille de lecture pour juger, vraiment, la performance d'un fonds :Pourquoi le TRI affiché par un fonds peut donner une image trompeuse de ce que vous allez réellement gagnerComment distinguer une performance construite sur de la vraie croissance opérationnelle de celle qui vient simplement d'un effet de levier ou d'une hausse des multiplesCe qu'une data room institutionnelle permet de voir, et que la plupart des investisseurs particuliers ne voient jamaisÀ partir de combien d'années un multiple de performance devient réellement significatifPourquoi la taille d'un fonds peut être un signal d'alerte plus fiable que son historique de performanceUn épisode pour ne plus se laisser impressionner par un chiffre de performance sans en comprendre la mécanique.-----------------------Ressources complémentaires sur cette thématique La fin de l'âge d'or du private equity : faut-il encore investir en 2026 ? https://sapians.com/blog/just-tips-criteres-investir-private-equityLa vérité sur les fonds evergreen : du private equity liquide, mais à quel prix ? https://sapians.com/blog/just-tips-fonds-evergreen-----------------------Attention : Les performances passées ne préjugent pas des performances futures et investir comporte des risques de perte partielle ou totale en capital. Ce contenu est informatif et ne constitue pas un conseil en investissement. Toute décision doit être adaptée à votre situation. Si vous souhaitez bénéficier de conseils personnalisés, veuillez créer votre compte ou prendre rendez-vous avec un conseiller Sapians.SAPIANS - RCS n°919 330 969 - ORIAS n°23003561 en qualité de CIF et COA. Activité de démarchage bancaire et financier.

Busy weekend of local short track racing. COA 300 at Oxford, NWMT at Seekonk, Thunder Road, Lee, and of course NASCAR at Chicagoland. Bob raced at Riverside. Brad DARF'd and Charlie reshingled his fish tank. All brought to you by the North East Short Track Network! Support the show

欢迎收听雪球出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。今天分享的内容叫招商轮船的发展历程和未来期望，来自赛艇队长。本文写自26年3月，修改于4月，发布于6月，仅做自己学习思考记录，不做任何推荐，请大家理性看待。文章目的是让大家全方位了解招商轮船这家公司，从而更好的判断公司价值。前言：招商轮船（股票代码：601872）是中国能源运输领域的龙头企业，隶属于百年央企招商局集团。回顾其发展历程，不仅是对一家企业的复盘，更是观察中国航运业在全球能源贸易格局演变中如何定位自身、把握机遇、应对挑战的绝佳窗口。从2014年国际油价断崖式下跌，到2022年俄乌冲突引发的能源危机；从2015年《巴黎协定》确立碳中和目标，到2025年全球能源转型加速；从传统的"石油世纪"向天然气、可再生能源并存的多元能源时代过渡——这些宏观背景的变迁，深刻塑造了招商轮船的战略选择。招商轮船从2015年还是一家以油轮运输为主业的单一型公司，到2025年已发展成为涵盖油运、干散货、LNG运输、汽车滚装、集装箱运输五大板块的综合能源运输集团，公司的业务边界、盈利结构、市场地位都发生了根本性变化。站在2026年的时点，回顾过去、展望未来具有特殊的意义。一方面，航运业正处于新一轮周期的起点，油运市场的景气度回升为公司业绩提供了支撑；另一方面，全球能源转型的大趋势不可逆转，LNG运输作为公司布局的战略性业务，正处于快速成长期，有望在中长期重塑公司的利润结构。一、发展历程：从单一油运到综合能源运输招商轮船的发展轨迹可以清晰地划分为三个阶段，每个阶段都有其鲜明的时代特征和战略主题。第一阶段：油运扩张与全球化布局（2015-2017年）2015年，招商轮船完成了对China VLCC的收购，这是公司发展史上的一个重要里程碑。主要整合了招商局集团旗下的大型油轮资产，使公司一举成为全球VLCC自有运力规模第一的船东。收购完成后，公司VLCC船队规模达到34艘，总载重吨超过1000万吨。这一规模优势不仅体现在运力绝对数量上，更体现在船队结构的优化上。收购的船舶多为2010年以后建造的新船，船龄年轻、油耗低、环保性能优良，符合当时IMO（国际海事组织）日益严格的环保法规要求。2016-2017年，国际油价在低位徘徊，中国作为全球最大的原油进口国，进口量持续增长。公司抓住了这一历史性机遇，通过VLCC船队的规模化运营，深度参与了"国油国运"战略。这一阶段的战略重点是做大。通过规模化扩张，公司确立了在VLCC领域的全球领先地位，形成了规模效应和品牌影响力。然而，单一依赖油运业务的风险也逐渐显现。2015-2016年，油运市场经历了从高位到低位的剧烈波动，公司盈利随之大幅波动。2015年公司实现归母净利润11.54亿元，ROE为10.01%；2016年净利润增至17.30亿元，ROE提升至11.91%；但2017年受市场低迷影响，净利润骤降至6.14亿元，ROE仅为3.89%。这一经历促使管理层开始思考业务多元化的必要性。到2017年底，自有VLCC增至44艘，租入VLCC 4艘，合计控制运力约1335万载重吨。与此同时，公司通过光租和代管方式扩大影响力，在国际油运市场的地位进一步提升。第二阶段：多元化战略启动（2018-2020年）2018年，招商轮船以发行股份购买资产的方式，收购了经贸船务下属的恒祥控股、深圳滚装、长航国际、经贸船务香港100%股权。这笔交易不仅解决了同业竞争问题，更重要的是实现了公司业务向干散货运输、滚装运输等领域的拓展。这次收购的战略价值在于：第一，获得了与巴西淡水河谷（Vale）合作的VLOC（超大型矿砂船）项目，使公司一举成为世界最大的VLOC船东之一。VLOC船型专门用于运输铁矿石，单船载重吨可达40万吨，是普通好望角型散货船的两倍以上。公司与淡水河谷签订的长期COA合同期限长达25年，为公司提供了极其稳定的现金流。第二，获得了深圳滚装的汽车滚装船队，为公司后来抓住中国汽车出口机遇奠定了基础。第三，获得了长航国际的沿海干散货和件杂货运输能力，形成了内外贸兼营的业务格局。2019-2020年，公司进一步通过子公司CLNG（与中海能合资）投资亚马尔LNG项目，进入LNG运输领域。亚马尔项目位于俄罗斯北极圈内，是全球最大的LNG项目之一。公司投资5艘ARC7级冰区加强型LNG船，用于运输亚马尔项目生产的LNG。虽然初期只是参股投资，但这是公司向清洁能源运输领域迈出的重要一步。这一阶段的战略重点是做宽。通过业务多元化，公司从单一油运向"油散并举"转型，降低了周期性风险。2020年，虽然疫情对全球航运市场造成冲击，但公司凭借多元化的业务组合，仍然实现了归母净利润27.77亿元，同比增长72.16%，充分验证了多元化战略的有效性。从财务数据看，2018年公司营业收入达到109.31亿元，较2017年的60.95亿元增长79.3%，这主要得益于经贸船务资产的并表。2019年营收进一步增长至145.56亿元，2020年达到180.73亿元。净利润方面，2018年为11.67亿元，2019年为16.13亿元，2020年跃升至27.77亿元，三年的ROE分别为6.40%、7.68%和10.73%，呈现稳步提升态势。第三阶段：综合能源运输成型（2021-2025年）2021年，是招商轮船历史上具有里程碑意义的一年。这一年，公司完成了对中外运集运的收购，正式进入集装箱运输领域。这笔交易完善了公司的业务版图，形成了"2+N"的业务格局——"2"指油运和干散货两大核心主业，"N"指LNG、滚装、集装箱三大补充业务。2021-2024年，全球能源市场经历了剧烈的波动。2021年下半年，全球供应链紊乱导致集装箱运价暴涨，CCFI指数一度突破3000点；2022年，俄乌冲突引发能源危机，油运市场出现脉冲式行情，VLCC TCE一度突破10万美元/天；2023-2024年，全球经济增长放缓，但区域市场分化明显。在这复杂的市场环境中，公司凭借多元化的业务组合，展现了强大的抗风险能力。特别想说的是，这一阶段公司在LNG运输领域取得了战略性突破。2022年，公司组建招商气运平台，开始自主投资、自主运营LNG运输业务。这一决策标志着公司从被动参股转向主动布局。2023年，公司成功获取卡塔尔能源LNG运输项目（卡气二期），这是公司历史上最大的单笔LNG运输项目。2024年，公司大规模下单，全年新签12艘LNG船。至此，公司累计投资LNG船舶64艘，其中61艘已锁定15-25年期长期租约，成为国际LNG运输市场不可忽视的重要力量。2025年，公司实现营业收入281.77亿元，同比增长9.22%；归母净利润60.12亿元，同比增长17.71%。与2015年相比，营收增长约3.2倍，净利润增长约3.4倍，总资产增长约1.3倍。成长是肉眼可见的。而且每一次周期的低点，都是轮船下一次成长的起点，每一次都是低价收购，周期高点的利润全部纳入公司。就跟木桶一样，一直在补短板，让公司的净利润越来越高。这和很多企业高位增发收购，最后一塌糊涂形成了鲜明对比。这是公司精细化运营的结果，希望公司不要因为这两年赚太多钱就飘了，还是要深耕价值，以合理甚至是低估的价格去收购资产，用好公司的每一分钱。二、财务表现：穿越周期的盈利能力财务数据是企业发展轨迹最客观的记录。通过分析2015-2025年的财务数据，我们可以清晰地看到招商轮船如何从一家依赖单一业务、业绩随周期剧烈波动的公司，成长为业务多元、盈利稳健的综合能源运输集团。营收与利润演变从营业收入看，公司经历了三个阶段的增长。2015-2017年，营收基本稳定在60-62亿元之间，这反映了公司当时以油运为主的业务结构，以及油运市场的相对平稳。2018-2021年，营收从109.31亿元快速增长至244.12亿元，年均复合增长率超过30%。这一增长主要得益于2018年收购经贸船务资产带来的并表效应，以及2021年收购中外运集运后的业务扩张。同期净利润也是跟随着水涨船高，在17年市场特别低迷的情况下也未亏损。18年之后净利润进入爆发期，逐年以30%+速度增长。2022-2024年，营收在257-297亿元区间波动，这反映了全球航运市场从疫情高点回落后的新常态。其中2022年，受俄乌冲突引发的能源危机推动，油运市场景气度大幅提升，净利润创下50.86亿元的历史新高（同比增长40.9%）。2023-2024年，虽然市场环境有所回落，但凭借多元化的业务组合和精细化的成本管控，净利润仍保持在48-51亿元的高位。2025年继续创历史新高。从数据可以看出几个重要趋势：第一，营收增长的波动性小于利润增长的波动性，这是因为不同业务板块的利润弹性不同。油运业务的利润弹性最大，干散货次之，LNG和集装箱相对稳定。第二，2018年后公司利润的周期性波动明显减弱，这得益于业务多元化。2017年净利润波动幅度超过60%，而2023-2024年波动幅度仅为5%左右。第三，2022-2024年，即使在油运市场周期性回落的情况下，公司仍能维持较高的利润水平，说明公司的盈利结构已经实现质的改善。资产与负债结构截至2025年底，公司总资产820.55亿元，较2015年的312.40亿元增长126.1%，年均复合增长率9.4%。资产规模的增长主要来自于业务扩张带来的船舶资产增加。2018年收购经贸船务资产使总资产从377.91亿元跃升至499.56亿元，2021年收购中外运集运使总资产从586.35亿元增至601.36亿元。资产结构也发生了显著变化。固定资产占比从2015年的约55%下降至2025年的约45%，这反映了公司业务从重资产的油运向相对轻资产的LNG运输（长期租约模式）转型。在建工程占比从2015年的约15%上升至2025年的约25%，这反映了公司LNG船舶订单的大规模增加。2025年在建工程的大幅增加，预示着未来几年LNG船队将进入集中交付期。从负债结构看，公司的财务杠杆保持稳健。资产负债率从2015年的56.1%上升至2018年的59.4%，随后逐步下降至2025年的47.6%。这一变化反映了公司盈利能力的提升和股东权益的积累。2015-2018年，公司处于快速扩张期，负债率相对较高；2019年后，随着业务逐步成熟和盈利积累，负债率持续下降。有息负债率保持在20-30%的合理区间。2015年有息负债约120亿元，2025年约150亿元，增幅远低于总资产增幅，说明公司的财务结构在优化。利息保障倍数从2015年的4.2倍提升至2025年的8.6倍，偿债能力显著增强。这一指标的提升，使公司在面对市场波动时具有更强的抗风险能力。盈利能力与股东回报从盈利能力指标看，公司的ROE呈现先降后升的趋势。2015-2017年，ROE从10.01%下降至3.89%，反映了油运市场的低迷和公司业务单一的风险。2018-2022年，ROE从6.40%逐步提升至17.11%，这得益于业务多元化带来的盈利结构改善和经营效率提升。2023-2025年，加权平均ROE为13.25%、13.21%、14.55%，在全球航运企业中处于领先地位。这一优势来源于两个方面：一是多元化的业务组合平滑了周期波动，二是长期合同的稳定贡献提供了可靠的收益基础。从股东回报看，公司始终坚持稳定的分红政策。2015-2025年，公司累计现金分红约120亿元，分红率平均约为43%。稳定的分红政策体现了公司良好的现金流管理能力和对股东的尊重。虽然分红率不是最高，但考虑到公司正处于LNG业务的快速扩张期，需要大量资本开支，这一分红水平是合理且可持续的。预计未来几年，随着LNG船队陆续交付并产生稳定现金流，公司分红能力将进一步增强。从整体财务数据来看，轮船整体非常稳健，但是又不失增长，一方面源于把握住了大部分的并购扩张机会，另外一方面新造船的规划也比较好，船龄也一直保持年轻化。股东回报虽然不是很高，但基于公司发展周期来看，还是可以的。未来希望能探索回购常态化的机制，让股东回报进一步增强。

Filho de Jair Bolsonaro foi pegou quatro anos e dois meses de prisão em regime semiaberto.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.    Transmissão ao vivo de segunda a sexta-feira às 12h no nosso canal do Youtube.  https://www.youtube.com/@OAntagonista  Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:  https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #Bolsonaro, #Eduardo, #STF, #Condenação, #Coação, #Justiça, #Julgamento, #Política, #Notícias, #Polêmica, #Bastidores, #Direito, #Debate, #Análise, #Podcast, #YouTube, #Trending, #Viral, #Alavancar, #Audiência

Tomorrow's podcast is a little different. We're doing a two-part episode. First, we're diving into some of the biggest health and peptide mistakes I'm seeing right now...mistakes that can waste money, delay healing, and in some cases actually make health challenges worse. Then we're going to celebrate one of our amazing CHI members, Susan, who chose a very different path. Instead of guessing. Instead of chasing symptoms. Instead of jumping from supplement to supplement, practitioner to practitioner, or peptide to peptide. She decided to understand what was actually standing in the way of her health. Susan completed advanced testing that revealed she was carrying and actively releasing pesticides, plastics, mold toxins, and other environmental toxicants. She learned where to focus. She followed a roadmap. And she took action. Before I tell you more about Susan's story, here's what we'll cover in today's episode:

ABOUT THE EPISODEListen in as David Schrock and Stephen Wellum interview Knox Brown on his COA essays, "Divine Energies: Eastern Orthodoxy's Strangest and Most and Most Important Doctrine" and "All Protestants God to Hell": Eastern Orthodoxy's Official Rejection of the Gospel at the Synod of JerusalemSponsorThis month's sponsor is Grimke Seminary. Pastors are called to care for the church of God that God called them to. So why do seminaries require men to leave their church to pursue theological studies? At Grimké Seminary, you can get Christ-centered, theological training in the Reformed, Protestant tradition, without leaving your local church. They offer a range of pastoral studies for students of all backgrounds to serve your growth in ministry, from a Bachelor's to a Doctor of Ministry.To apply, go to grimkeseminary.org and use the code “christoverall” to have your application fee waived.Timestamps00:37 – Intro04:43 – Knox's Exposure to Eastern Orthodoxy07:10 – Hans Boersma10:46 – Knox's Article on the Doctrine of God13:10 – Essence and Energies17:14 – Explaining How the Energies are Existing Enhypostatically19:56 – What Does Being Canonized Mean?21:40 – How Does This All Relate to the Economic Trinity?24:12 – In EO, How Do We Share in the Energies?29:27 – Sponsor: Grimké Seminary36:37 – The Council of Jerusalem38:57 – Is Cyril Lukaris Still a Saint?40:10 – How Prominent is the Council of Jerusalem?43:45 – Different Weights and Measures on Schism53:40 – Reading the Councils to Know What You Gain and What You Lose in EO57:35 – OutroResources to Click“Divine Energies: Eastern Orthodoxy's Strangest and Most Important Doctrine” – Knox Brown“All Protestants Go to Hell: Eastern Orthodoxy's Official Rejection of the Gospel at the Synod of Jerusalem” – Knox Brown“The Acts and Decrees of the Synod of Jerusalem, Sometimes Called the Council of Bethlehem, Holden under Dositheus, Patriarch of Jerusalem in 1672”“The Delayed Synodical Receptions of the Councils of Jasy (1642) and Jerusalem (1672)” – Craig Truglia“Georgian Orthodox Church” – Wikipedia“When Did Today's Autocephalous Churches Come Into Being?” – Orthodox History“Eastern Orthodox and Oriental Orthodox: What's the Difference?” – TheoriaTheme of the Month: Go West, Young Men: Evaluating the Drift toward Eastern OrthodoxyGive to Support the Work

226: On this episode, we are back from a week away because of setup and working the 2026 Northern Illinois Section Championship! Springfield offers a stripper version of the Echelon and COA on the Prodigy LSI looks to have a new 2011 grip in the horizon with removable grip panels Jaki shoots her first major in a long time Tony has a HORRENDOUS start to his match! Check Out Our Partners & Affiliates For The Best Deals On Gear:

226: On this episode, we are back from a week away because of setup and working the 2026 Northern Illinois Section Championship!Springfield offers a stripper version of the Echelon and COA on the ProdigyLSI looks to have a new 2011 grip in the horizon with removable grip panelsJaki shoots her first major in a long timeTony has a HORRENDOUS start to his match! Check Out Our Partners & Affiliates For The Best Deals On Gear:

"Mother Nature provides us with all the food and medicine that we need. Food is medicine — and it is the number one thing you can do for any person or animal to help them stay healthy and help their immune system operate." This episode is sponsored-in-part by Maddie's Fund, OcuTrap, and The Kitten Conference. What if the best medicine for your community cats isn't found in a bottle — but in a bowl? In this episode, host Stacy LeBaron sits down with Angela Ardolino, a certified cannabis and fungi clinician with over 20 years of expertise in holistic pet wellness and founder of MycoDog, MycoCat, and CBD Dog Health. Angela's path to holistic animal care began with her own recovery from rheumatoid arthritis using plants, mushrooms, and diet — which led her to discover that every animal shares an endocannabinoid system, the body's master regulatory system. With no quality animal products on the market, she spent two years formulating and testing full-spectrum hemp extract and medicinal mushroom tinctures at her rescue farm before bringing them to the public. Stacy and Angela dig into the real cost of kibble — not just financially, but biologically — and make the case for real food, even in small increments, for both owned cats and colony cats. Angela also offers practical guidance on supporting senior and geriatric cats with full-spectrum hemp extract, how to spot trustworthy supplements (look for a COA), and why the endocannabinoid system is the key to keeping cats healthy from the inside out. Press Play Now For: Why kibble is the wrong foundation for feline health — and practical, budget-friendly alternatives for pet owners and colony caregivers alike How the endocannabinoid system works in all animals and why supporting it is key to preventing disease How to administer full-spectrum hemp extract to cats you can touch — and cats you can't Why 85% of supplements on the market (for pets and humans alike) aren't worth buying, and how to identify the ones that are When a cat becomes a "senior" vs. a "geriatric" — and why that distinction matters for their care The feline grimace scale, telehealth options, and emerging tools that help caregivers monitor cats without a vet visit A vision for mobile veterinary care that extends to colony sites, not just indoor pets Resources & Links Angela Ardolino's Website CBD Dog Health MycoDog Your Natural Dog Podcast Follow Angela on Instagram Follow Angela on Facebook Follow Your Natural Dog on Instagram

In Loosdrecht, IJsselstein en Den Bosch liep het verzet tegen nieuwe asielzoekerscentra de afgelopen weken uit de hand: de politie werd bekogeld, een snelweg bezet en ruiten van gemeentehuizen sneuvelden. Tegelijkertijd moet het COA nu al onmenselijke keuzes maken, ziet redacteur Martin Kuiper. Komen we hier nog uit?Gast: Martin KuiperPresentatie: Bram EndedijkRedactie: Elze van Driel & Yara van HeugtenMontage: Andy ClarkEindredactie: Anna KorterinkCoördinatie: Ilse EshuisProductie: Rhea Stroink Heb je vragen, suggesties of ideeën over onze journalistiek? Mail dan naar onze redactie via podcast@nrc.nl.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

De asielcrisis loopt vast, de onvrede in de samenleving groeit en de AIVD mengt zich nadrukkelijk in het publieke debat. Worden de spelregels van onze democratie herschreven?In deze uitzending van DNW Politiek gaan Ad Verbrugge en Jelle van Baardenwijk in gesprek met Jasper van Dijk over de explosieve situatie rondom de asielopvang. De beelden van de burgemeester in Loosdrecht en de noodkreet van het COA laten zien dat de rek er bij zowel het bestuur als de bevolking volledig uit is. Is er sprake van onmacht, of kijken we naar een bewuste beleidsagenda die aanstuurt op een paradigmawisseling?Daarnaast duiken we in het recente jaarverslag van de AIVD. De inlichtingendienst waarschuwt voor 'anti-institutioneel extremisme' en 'narratieven' in alternatieve media. Maar wie bepaalt wat desinformatie is en wat een legitieme afwijkende mening? Ad en Jelle analyseren de gevaarlijke grens tussen veiligheid en het monddood maken van overheidskritiek.-------------Steun DNWMaak het geluid van de Nieuwe Wereld mogelijk. Zonder uw steun geen DNW! Word lid of doneer:

Vandaag is Robert Paul Schwippert te gast bij Jelle van Baardenwijk. Robert Paul maakte een opmerkelijke carrièreswitch: van organisatieadviseur in de internationale olie-industrie naar casemanager bij het Centraal Orgaan opvang asielzoekers (COA). In zijn boek 'In de wachtkamer van de toekomst' deelt hij zijn ervaringen van de werkvloer in het azc van Almere.In dit gesprek duiken we in de weerbarstige praktijk van de asielopvang. Robert Paul legt uit hoe het systeem momenteel vastloopt: van statushouders die jarenlang tussen "dunne wandjes" wachten op een woning, tot de frustrerende bureaucreatie rondom werkvergunningen en taalonderwijs. Waarom verspillen we zoveel talent? En hoe kunnen we de dialoog tussen het azc en de samenleving herstellen?In dit gesprek bespreken we de cultuurshock van een consultant binnen het COA en analyseren we waarom de inburgeringswet in de praktijk vaak te laat start. Ook staan we stil bij het contrast tussen hoopvolle nieuwkomers en de neerslachtigheid die ontstaat door het lange wachten. Daarnaast komt de impact van de Spreidingswet aan bod.--------Koop nu je kaartjes voor de Theater Tour! ⭐7 mei: Op Hodenpijl, Schipluiden met Kees de Kort: https://ophodenpijl.nl/evenement/nieuwe-wereld-kees-de-kort/?occurrence=2026-05-0719 mei: Grote Kerk Alkmaar met Maurice de Hond: https://grotekerkalkmaar.nl/tickets/seizoen-25-26/de-nieuwe-wereld-ondergang-van-het-avondland/?showId=3878151937-177159177816 juni: De Maagd, Bergen op Zoom: Willem Middelkoop: https://www.demaagd.nl/agenda/ondergang-van-het-avondland-de-nieuwe-wereld-4xn6Bestel het boek van Robert Paul: https://vangennep-boeken.nl/in-de-wachtkamer-van-de-toekomst-robert-paul-schwippert?srsltid=AfmBOoowhFK0w9eWWjYE9cMilGmddKBHFwguclVZE8g8VYIPIQkhnE51

Michael Jewett is a pioneer of cell-free biotechnology. Instead of using living microbes as factories, he uses their internal molecular machinery to make valuable proteins, medicines, diagnostics, and other chemicals. Jewett recently used the technique for vaccine production in an approach that could produce up to 150,000 doses from one liter. He believes cell-free biotech could democratize the production of essential medicines, improve water safety, and help convert atmospheric carbon into useful products, among other promising possibilities. “It's just-add-water biotechnology,” Jewett tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Michael Christopher Jewett Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces Mike Jewett, a professor of bioengineering and chemical engineering at Stanford University. (00:03:23) What Is Cell-Free Biotechnology? Using the internal machinery of cells without the cells themselves. (00:04:20) Removing “Evolutionary Baggage” Why cells' natural priorities can conflict with engineering goals. (00:07:41) Advantages of Cell-Free Systems From large-scale production to decentralized, on-demand manufacturing. (00:11:40) Making Proteins Outside Cells How DNA instructions are used to produce functional proteins. (00:13:49) Biosensors for Water Safety Detecting contaminants like lead using engineered proteins. (00:17:05) Engineering Better Sensors Improving sensitivity and selectivity through protein design. (00:20:33) AI in Bioengineering How data and models accelerate discovery and design. (00:23:22) Sustainability & Carbon Capture Turning atmospheric carbon into useful chemicals. (00:26:18) Building New Biological Pathways Combining chemistry and biology to create novel production systems. (00:27:54) From Molecules to Materials How acetyl-CoA enables fuels, plastics, and other products. (00:30:51) Teaching Biotechnology Making biotech accessible through hands-on, “just-add-water” kits. (00:33:12) Future In a Minute Rapid-fire Q&A: innovation, collaboration, and the future of biotech. (00:35:32) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rep. Terry Ridon speaks with Christian Esguerra on the latest COA notice of disallowance on Sara Duterte's confidential fund.

With April showers upon us, I address your Biohacking and Lifehacking questions in this rare livestream Q&A. And we chat with our chipper friend Daniel about Psalm 23 and mental health...5:40 Biohacks for OCD9:50 SKQ1 for Dry Skin14:25 COA-verified Methylene Blue?17:05 Piracetam Dosage20:15 Is Piracetam Hepatotoxic?23:20 Visoluten vs Visomitin for Macular Degeneration27:55 Nootropics Vendors in Australia31:20 Psalm 23 for mental healthRead

Roger and Annie check in mid-tax-season with a candid look at what's actually landing on desks — from W-2s showing overtime pay coded a half-dozen different ways to clients convinced their entire salary qualifies for the new deduction. They also break down the meal and entertainment changes taking effect in 2026, including why your office coffee pot is now a tax problem.SponsorsPadgett -  Contact Padgett or Email Jeff PhillipsGet NASBA Approved CPE or IRS Approved CELaunch the course on EarmarkCPE to get free CPE/CE for listening to this episode.Chapters(00:00) - Mardi Gras Catch Up (01:53) - Tax Season Pulse Check (05:17) - New Tips and Overtime Law (07:07) - Tracking and Payroll Prep (10:58) - New Fees and Tip Confusion (12:46) - W2 Example Box 14 Codes (16:25) - Should We Ask About Overtime (20:36) - OT Premium Smell Test (24:39) - Weird W2 Overtime Codes (27:04) - Pay Stub Premium Math (29:25) - Pay Stub Math Costs (29:55) - Overtime Premium Basics (32:13) - W2 Box 14 Overtime (33:27) - When Details Are Missing (35:35) - Double Overtime Limits (36:18) - Salary vs Overtime Claims (38:36) - Due Diligence and Fees (41:01) - Meals Rules Change 2026 (45:01) - Zero Deduction Office Meals (45:37) - Coffee and Snacks Debate (48:59) - Client Education and COA (51:48) - IRS Paper Checks Ending (55:49) - Wrap Up and Next Steps Follow the Federal Tax Updates Podcast on Social Mediatwitter.com/FedTaxPodfacebook.com/FedTaxPodlinkedin.com/showcase/fedtaxpodConnect with the Hosts on LinkedInRoger HarrisAnnie SchwabReviewLeave a review on Apple Podcasts or PodchaserSubscribeSubscribe to the Federal Tax Updates podcast in your favorite podcast app!This podcast is a production of Earmark MediaThe full transcript for this episode is available by clicking on the Transcript tab at the top of this pageAll content from this podcast by SmallBizPros, Inc. DBA PADGETT BUSINESS SERVICES is intended for informational purposes only.

What if the reason you’re not healing isn’t that you need another diagnosis? 0:08 It’s that your cells aren’t receiving the right signals. Because the body doesn’t run on diagnosis, it runs on 0:16 communication. And peptides are one of the most powerful, most misunderstood 0:21 tools we have for cellular signaling, immune balance, tissue repair, gut 0:27 lining support, metabolic control, brain signaling, sleep cycles, and even sexual 0:35 wellness. Today, I’m going to do what most people won’t. Define peptides in 0:41 plain English for you. break them into categories by what they’re best at and 0:47 tell you which ones are FDA approved on the list and which ones are commonly 0:53 used off label or investigational with the evidence that actually says these 1:00 work. This is going to be a powerful episode and if you’ve ever felt like you’re hearing hype without clarity, 1:07 this one’s for you. So, as usual, grab your cup of coffee or tea and settle in 1:13 as we talk about peptides that can fit into your healing journey. We’re going 1:19 to have a short word from our sponsor. You know, we got to do that. That’s how we stay on the air here. So, we will be 1:26 right back after this. Did you know sweating can literally heal your cells? 1:32I nfrared saunas don’t just relax you. They detox your body, balance hormones, 1:37 and boost mitochondrial energy. I’m obsessed with my health tech sauna. And 1:42 right now, you can save $500 with my code at healthtechalth.com/drmuthqen25. 1:54 All right, here we go, guys. I am excited to dive into peptides with you. 2:00 So understanding peptides is foundational, right? And I’ve been 2:06 studying peptides now for about nine years. Um, and I find that they are 2:13 incredible. Um, so I want to break down for you what peptides actually are, what 2:19 they do, and some of the top peptides that are available today, and how they 2:25 can be utilized. Because I think it’s really important. And I think it’s it’s there’s a lot of confusion out there about what these things actually are and 2:32 are they safe? Are they not? When do we use them? What’s the science behind them? So, we’re going to dive in and 2:38 we’re going to talk about all things peptides. So, let’s get ready here. Here we go. So, peptides are short chains of 2:45 amino acids and they typically range anywhere from 2 to 50 amino acids and 2:51 they’re linked by peptide bonds. So think of them as the superglue that holds the amino acids together. They sit 2:58 between the amino acids and they are full proteins in terms of their size and 3:04 their complex structure. And what makes peptides particularly interesting in 3:10 medicine is their role as signaling molecules. They’re essentially the 3:15 body’s text messages carrying specific instructions to cells and tissues. And 3:21 unlike our proteins which often serve as structural roles or act as enzymes, 3:28 peptides typically function as hormones, neurotransmitters and growth factors and 3:33 they bind to specific receptors on the cell’s surfaces or within the cells and 3:39 they trigger this effect. It’s like a cascade effect of a biochemical reaction 3:45 that ultimately changes the cellular behavior. So basically, it’s changing 3:50 the way the body’s cell structure acts. And this is why peptides can be so 3:56 incredibly powerful and therapeutic when you introduce the right peptide signal. 4:02 Now, you could theoretically redirect cellular processes toward healing, 4:07 towards metabolism, immune balance, tissue repair. Any of those things can 4:14 be manipulated to do a certain thing once we add the peptide. The challenge 4:19 in peptide medicine though lies in distinguishing between those peptides that have been rigorously studied, 4:26 proven safe and effective and approved by regulatory bodies like the FDA versus 4:31 those that exist in what we call the gray zone of a promising clinical data. 4:36 But they really lack human validation so far. And this distinction is critical because the presence of a plausible 4:43 mechanism does not guarantee safety or efficacy in living humans. So, this is 4:50 really important and we’re going to dive in and look at some of the research on all of these different peptides that are 4:56 available and I’m excited to say there’s some amazing peptides being studied right now that unfortunately are not 5:01 available. But I can’t wait to see them hit the market for us because it is going to be a gamecher as far as health 5:09 and longevity. So there is a quality control issue and there is a hidden 5:14 variable in peptide medicine with this and it’s one of the most underappreciated aspects of peptide 5:21 therapy particularly for non-FDA approved peptides. It’s quality control. 5:26 When we discuss pharmaceutical medicines, we take for granted that the pill contains what the label says. Not 5:32 always true depending on where it comes from. You guys, if you’ve heard my episodes before talk about how many of our medications are made in China and 5:41 have been contaminated with other things, you will realize that that is not always true. So, just because it has 5:48 the FDA stamp of approval on the medication, it still does not necessarily mean it’s safe and we still 5:54 need to do our homework on it. So, sorry for digressing on you guys, but you know, when we get a medication, we we 6:00 think that what the amount says is what is there, doesn’t have contaminants, it’s manufactured with good 6:06 manufacturing practices. You’ll see that listed as GMP on the bottle, and it’s been stored properly, it’s been 6:12 maintained stable, and with research peptides and compounded formulations, 6:17 none of this can be assumed. So, I will share a story with you. There was a gentleman that was purchasing these 6:24 peptides online from a research facility and um did not know that they were 6:30 coming from China and he was ordering a particular growth hormone peptide and 6:35 after a little while he had he had done fine for the few first few bottles. After a little while he started having 6:42 some complications. He started getting really irritable and angry and ragy and 6:47 he didn’t quite know what was going on. And so he decided to go get some testing done. He had some blood testing done and 6:53 his testosterone level was over 5,000. So for those of you who know what testosterone level should be for a guy, 7:00 they really shouldn’t be any higher than about 1,00200 would be absolute max that we’d want to see. Now he was taking 7:06 testosterone but not to that degree. And prior to adding this peptide, his 7:12 testosterone was very stable. What they ended up finding out was the peptide that he was getting, whoever was 7:18 manufacturing it added testosterone to the peptide. They felt like if if it had growth hormone, that was great, but if 7:25 it had growth hormone and tes testosterone, all the better. And he didn’t know that. And this is the 7:31 problem that we can have with peptides if you don’t source them properly. if you’re not working with somebody that 7:37 knows how to source them and can prove that they are what they say they are. Um, I’m sure there’s a whole bunch of 7:42 studies out there too of people getting these peptides and paying hundreds of thousands of dollars for them over their 7:48 lifetime and finding out they were nothing more than just sterile water. So, you really do need to be careful 7:53 with your quality control. Now, this kind of leads us right into the next topic that we’re going to talk about and that’s the manufacturing question, 8:00 right? The FDA approved peptides are manufactured in facilities subject to 8:05 the FDA inspection rules following our GMP regulations and these facilities 8:11 must validate their manufacturing process, demonstrate consistency batch to batch, test for purity and potency. 8:18 They need to test for bacterial endotoxins and sterility and they need to maintain detailed records. So, when a 8:25 pharmaceutical company submits a drug application, the FDA inspects the manufacturing facility as part of the 8:32 approval process. If you’re getting peptides from a different country, none of that is happening. And there are some 8:38 ways for us to determine if that is what you’re getting. Typically, the rule of thumb is if your peptides are coming 8:44 with a different colored top, every one of them has a different colored top. Those are typically being sourced out of 8:49 China. I wouldn’t say that’s 100% but that’s kind of the rule of thumb that people follow. So compoundingies these 8:56 are thearmacies that make our bio identical hormones. They can make medications in any dose or strength or 9:02 route. There are thousands of them in every not that not in every state but 9:08 there are thousands of them around the country right now. So these compoundingies are registered as 503A 9:15 facilities. They do traditional compounding for individual prescriptions, right? Like they can make 9:20 thyroid, they can make LDN, they can make estrogen. You can also have a 503b 9:27 facility, which is an outsourcing facility. And these companies produce larger batches of products. They’re they 9:34 have some oversight, but they’re less stringent than for FDA approved 9:40 manufacturers. And state boards of pharmacy regulate a 503A pharmacy. And 9:45 the FDA can inspect the 503b facility, but doesn’t preapprove any of their 9:52 compounding products. So, they can inspect it, but they don’t approve them. So, research chemicals and these 9:58 suppliers operate essentially with no oversight. They explicitly market products for research use only, not for 10:06 human consumption to avoid FDA regulation. If they put that on their 10:12 product, they don’t have to comply to what the FDA is saying. And there is no required manufacturing strategies or 10:19 standards, no required testing, no required sterility assurance, and no enforcement mechanisms if products are 10:26 mislabeled or contaminated. So basically, they don’t have the liability, but that doesn’t mean that 10:31 all of them are badies or bad suppliers. It just means they don’t have to comply 10:37 to the FDA rules. Now, there are many of these companies that I’ve seen and I’ve talked to that do do a lot of this. They 10:44 do test their product for sterility. They do test their product to make sure it is what it says it is. They don’t 10:51 have to, but they do. So, if you’re going to decide to use a company that 10:56 has research only, not for human consumption, at least ask for their 11:02 proof of testing so that you know that the product you’re getting is what it says it is and that it’s clean. Because 11:08 this is where we run into the problem is in purity. So in purity peptide 11:13 synthesis can produce not just the targeted peptide but also related 11:19 peptides with deletions, substitutions, truncations or truncations of amino 11:25 acids. Sorry. And this high performance liquid we call it uh chromatography can 11:30 separate these related impurities and quality and quantify the actual target 11:35 of the peptide content. So a certificate of analysis is what you want to ask these companies for. This shows the HPLC 11:44 the testing mechanism with greater than 95% or ideally 98% purity which 11:51 indicates a higher quality product. So this certificate of analysis can be fabricated may not represent the 11:57 specific batch being sold. It happens. We need to know not everybody is honest. Not everybody, you know, does what they 12:03 say and it does what’s right. But at least you at least they’re giving you something and you have some security. 12:10 and then choose a company that was referred to by someone else that has done some homework as well. In in 12:16 commercial research, there’s independent testing and they research peptides and this has been really shocking 12:23 variability that they’ve seen. Some products contain 50% or less of the 12:29 claimed peptide and some contained primarily degradation of the product or manufacturing impurities and some 12:36 contained bacterial endotoxins at levels that could cause fever and systemic 12:42 inflammation if it was truly injected. And I would also worry with some of those problems, you know, depending on 12:48 what impurity or bacterial endotoxin was there. If you’re using a product to boost your immune system and your immune 12:54 system is already compromised, these bacterial endotoxins can actually make you sicker instead of what you want it 13:02 to do, which is making you better. So, sterility is always an issue with anything that is manufactured, 13:08 especially things that we’re doing as an injection. Peptides are intended for injection. They must be sterile. They 13:16 must be kept safe. And pharmaceutical manufacturers conduct this sterility testing on every batch. 13:22 Compoundingarmacies should conduct sterility testing particularly for high-risisk compounded 13:28 sterile preparations and research chemical suppliers may or may not conduct any testing. So injecting 13:35 non-sterile material can cause local infections, abscesses at the injection 13:41 site and or if the bacteria enters the bloodstream could potentially be 13:46 life-threatening and you could have sepsis. Now, excuse me. We saw this 13:52 happen in a compounding pharmacy uh gosh, it’s probably been 10 years ago 13:57 now, I think. um they unfortunately had a strep uh contamination in their 14:03 product and they weren’t testing it. It was a large compounding pharmacy out of Florida and they were making products 14:08 that were being injected into the joints and um these people got very very sick 14:14 and some of them died and um some of them got very very injured by this uh 14:21 complication that happened. So it’s not like this doesn’t happen. It does, but it doesn’t happen often. And that’s what 14:28 we have to know about. And so, when we’re talking with you guys about storage and stability, it’s really 14:34 important to make sure you maintain your peptides well. So, many peptides are unstable at room temperature. They 14:41 require refrigeration or freezing. We tell everyone to make sure you’re refrigerating your peptides. That way, 14:48 there’s no question about it. when it stays cold um it prevents or slows down 14:54 the process of uh bacteria growing in it. So some of these peptides actually 14:59 degrade very rapidly in the solution and they must be reconstituted immediately before use and reconstitution of the 15:07 peptides really has limited stability often just days to weeks not months. So 15:13 improper storage, temperature, um changes during shipping or prolonged 15:19 storage of a reconstituted product can lead to degradation into inactivity or 15:25 potentially even a harmful breakdown of the product itself. So if you have a product that’s been sitting in your 15:30 refrigerator for a month or two months or 3 months or 6 months, just throw it away. It’s not going to be any good. 15:37 you’re not going to actually get the peptide and the uh potency that you’re looking for anyway out of it and the 15:44 potential of you introducing an endotoxin, a bacterial endotoxin is quite high at that point. So you just 15:50 really don’t want to take the risk, excuse me. So what practitioners, what 15:56 should we do and what should patients do? Well, for any peptide therapy, we 16:03 want to source our verification. know where the peptide product comes from. Is 16:08 it an FDA approved product? Is it a 503b compounding? A research chemical 16:14 supplier? Is there a certificate of analysis? Request and review this COA. 16:20 And you want it to show purity greater than 95% but ideally greater than 98%. 16:27 You want that identity be identity to be confirmed by mass spectromedy. Uh 16:33 sterility testing should be done. Bacterial endotoxin testing should be done. Batch number matching of the 16:39 product that you received should be done. Proper storage. You want to know that this has been refrigerated or 16:46 frozen as directed once it’s been mixed. Look at the expiration dates for reconstituting your peptides. Track that 16:53 reconstitution date and discarded accordingly like we just talked about. Monitor for your adverse effects. Even 17:01 with the perfect quality control, monitoring for adverse effects is essential with questionable quality and 17:08 vigilance is really critical here. I know it’s frustrating for a lot of patients when they have to get several 17:15 bottles and they only last a week or two. right here, you guys. This is why 17:21 they only last a short period of time because once they’re mixed, they start 17:26 to degrade and they won’t be good and you won’t get the benefit from it. So, 17:31 it’s really important with these research peptides specifically, practitioners should recognize that all 17:38 recommending products without quality assurance violates the fundamental medical principle of first do no harm. 17:45 If a patient is determined to use research peptides despite counseling, providing guidance on quality 17:52 verification, requesting those COAs, using pharmaceutical grade sources when available, proper testing, this all 17:59 reduces harm, but doesn’t constitute necessarily that recommendation. Now, 18:06 that being said, today it’s very difficult to find peptides by the compoundingies because of what the FDA 18:13 has done. So most of the peptides that are available to us have been labeled 18:18 not for human consumption, not because they’re not good products, but because 18:25 of what the FDA did. And this is how these companies have been able to 18:31 continue to provide peptides to the medical community. And if you know you 18:36 have a good company, then you’re, you know, you’re still taking the risk, right? But at the end of the day, the 18:42 reason they’re doing that is to protect themselves from the FDA, from liability. Um, so just kind of know that there is 18:50 some talk in the community with um Bobby Kennedy that this is going to change and 18:55 they are going to bring peptides back to the compounding pharmacies. Now, we don’t know which ones they’re going to 19:01 bring back. Uh, will it be all of them? Will it just be some of them? What’s going to happen here? Um, is it going to 19:07 go to the pharmaceutical companies like our GLP1s did? We don’t know what that’s going to look like quite yet. Um, but it 19:14 is coming and that is positive news. So, let’s talk now about FDA approved 19:21 peptide medications. So, this is the metabolic revolution, right? GLP1 19:28 and our dual increeting agonists. This is an exciting time. GLP-1s are amazing. 19:35 Um, a lot of people are skeptical, a lot of people love them, a lot of people hate them. Whichever side of the fence 19:42 that you’re on, I understand. But I want to talk about the science of it today 19:48 and what it actually means for people. So, the story of GLP1 glucagon like 19:54 peptide one represents one of the most significant advances in metabolic 19:59 medicine in the past several decades. GLP-1 is an accretin hormone. It’s 20:05 gutder derived peptide that potentiates insulin secretion in response to food 20:11 intake. And the body naturally produces GLP-1 in the intestinal L cells, but it 20:17 rapidly degraded by the enzyme DPP4 giving it a halflife of only about 2 20:24 minutes. So this rapid breakdown made in therapeutically impractical until 20:31 research was developed and modified the analoges that resist the enzyme degradation. So for those people who 20:39 never feel full when they’re eating, never feel satisfied when they’re done, this is because their body is either not 20:46 producing enough GLP1 or it’s not getting the signal right. And this is a 20:51 leptin issue. This is an insulin issue. It’s a GLP-1 issue. It’s a complicated 20:56 issue. This is not anything that the person is doing wrong. It’s what is happening to their body. And so GLP1s 21:03 have really revolutionized this. So one particular GLP-1 that we have is 21:09 semiglutide. And this GLP-1 agonist is what changed everything in the world of 21:16 metabolic medicine. Semiglutide is marketed as ompic for type 2 diabetes 21:23 and it’s marketed as WGOI for chronic weight management. It is a modified 21:29 GLP-1 analog with 95 or sorry 94% amino acid sequence uh homology to human 21:37 GLP-1. So it means that it’s it’s just like our own GLP-1 that we make. This 21:42 modification includes specific amino acid substitutions and the addition of C18 21:50 a fatty acid chain which allows the peptide to bind to albumin. Now this 21:56 albumin binding dramatically extends the half-life to approximately one week 22:01 enabling one weekly dosing which is a major advantage over the earlier GLP-1 22:07 agonists that require daily or twice daily injections. The mechanism by which 22:13 semiglutide works is multiaceted. At the pancreatin level, it binds to GLP-1 22:20 receptors on the pancreatic beta cells enhancing glucose depending sorry 22:27 enhancing glucose dependent insulin secretion. This glucose dependency is 22:33 crucial. It means the peptide only stimulates insulin release when blood glucose is elevated. This dramatically 22:41 reduces the hypoglycemic risk compared to insulin or even uh sulfuras. 22:47 Simultaneously semiglutide suppresses glucagon secretion from pancreatic alpha 22:53 cells further improving glycemic control. This is really amazing because 23:00 over the years when we’ve used insulin, which is also a peptide by the way, you 23:05 had to dose it just right because if you didn’t, you would produce so much insulin that it would crash the blood 23:12 sugar and then somebody would have too low of a blood sugar. They’d be hypoglycemic and they’d have to eat more 23:18 sugar and then they’d have to modify the insulin again and the person would be going up and down, up and down, up and 23:24 down all day long. And that created a lot of problems for people and so this 23:30 helps to stabilize that so it is not such an intense change. Now in the GI 23:36 tract semiglutide delays the gastric emptying particularly pronounced during 23:41 the initial weeks of therapy. This slowing of the gastric emptying contributes to the sensation of being 23:48 full and early satiety that patients often describe. However, this effect 23:54 tends to attend to weight over time as the body adapts through the appetite 24:00 suppressing effects generally persist through central mechanisms. So, when we 24:05 talk about what is actually happening, we’re slowing that digestive process down. That’s why people aren’t so 24:11 hungry. It’s why they’re not eating so much. This is why people can develop constipation with these products because 24:17 it’s slowing the body’s digestive tract down. Now some people will call this 24:22 gastroparesis. Um gastroparesis is actually different. 24:28 It is when we lose control over what’s happening in the in the colon like the 24:34 nerves and things like that just stop working. I have never seen that with the GLP1s that we prescribe in micro doing. 24:42 um it’s been documented. It can happen, but again it a lot of it is dosing and a 24:48 lot of it is staying on top of your client and what’s happening and what’s going on and what you’re doing and making sure that they do have good 24:54 motility still. So a lot of these things can be mitigated if you have problems 24:59 with them. Now one of the most profound effects of semiglutide occur in the 25:05 central nervous system. GLP-1 receptors are widely distributed in the brain 25:10 particularly in the hypothalamus and the brain stem area where we are involved in 25:15 appetite regulation. So when when wilding and colleagues published their 25:20 landmark step one trial in the New England Journal of Medicine in 2021, 25:25 they demonstrated that participants receiving 2.4 4 milligrams of semiglutide weekly achieved an average 25:32 weight loss of 14.9% of their body weight over 68 weeks. Now, I want you 25:39 guys to really understand this. We’re talking roughly 15% body weight loss 25:45 over a year, longer than a year. 52 weeks is a year, right? This is 68 25:50 weeks. So, it took longer for them to lose. We’re not talking about giving 25:55 somebody a dose to lose 15% of their body mass in a month or two. That that 26:01 is not healthy for any of us. That is not what we’re talking about doing here. Now, they compared this to placebo and 26:08 the placebo was only 2.4%. So, that is a significant difference. 26:14 And even beyond the numbers, patients reported something very qualitatively different, a reduction in what’s now 26:21 called food noise. Everybody knows what food noise is. We’ve talked about this long before GLP1. It’s that craving. 26:28 It’s that part of your brain that just keeps thinking about I want to eat something. You know, that was actually 26:34 reduced and they didn’t expect to see that happen. Now, this refers to the constant mental preoccupation with food, 26:42 the intrusive thoughts about eating, the difficulty in feeling satisfied. Semi-glutide appears to appears to 26:49 modulate reward pathways in the misolyic system reducing hedonic eating and food 26:57 cravings. Now there are also great cardiovascular effects of semiglutide 27:02 that extend beyond weight loss. Uh the sustained six and select trials 27:07 demonstrated significant reductions in major adverse cardiovascular events uh 27:14 mace in high-risisk populations. The select trial published in 2023 showed 27:20 that semiglutide reduced cardiovascular death, non-fatal myioardial inffection 27:25 and non-fatal stroke by 20% in adults with overweight or obesity and 27:31 established cardiovascular disease but without diabetes. So this suggests that 27:37 mechanisms beyond glucose control and weight loss possibly including 27:42 anti-inflammatory effects, improvements in endothelial function and favorable 27:47 changes to lipid profiles. Now I will tell you the clients that I work with that are on GLP1, 27:53 they will tell you that their inflammation has been significantly reduced. We are also seeing really 28:00 amazing results in lipid profiles. um part of its weight loss, but there is a 28:06 component to this that is lowering the triglyceride levels because it’s related to sugar and how the body’s processing 28:11 it. And we’re seeing better profiles, less need for statins as a result of 28:17 that. If if you want to listen to my episode on statins, I have one on that. Uh they are not my favorite medication. 28:24 I think it’s overprescribed and overused um and not really affecting or 28:29 addressing the problem. So these things can really be helpful. There’s also some 28:34 uh ramblings going on with GLP-1s saying that they may be able to help with 28:40 addiction in the future because of where they’re finding it affecting the brain and how it affects the food noise and 28:47 the cravings that we have for food and the addiction for food. Could it potentially help with other addictions 28:53 down the road? We’ll have to wait and see on that one. So semiglutide’s FDA prescribing information also includes a 29:00 box uh boxed warning about thyroid sea cell tumors. So in rodent studies 29:06 semiglutide caused dose dependent and treatment duration dependent sea cell 29:12 tumors at clinically relevant exposures. So while it’s unknown whether or not 29:17 semiglutide causes uh thyroid cancer tumors in humans and the rodent thyroid biology 29:26 differs significantly from humans, the drug is contraindicated in patients with a personal or family history of 29:33 medillary thyroid carcinoma or in patients with multiple endocrine neopl neoplasia syndrome type two. it is 29:42 uh contraindicated for safety effects with that. Um I have seen endocrinologists okay GLP1s to be used 29:50 in patients who’ve had other forms of thyroid cancer just not the meillary 29:55 thyroid cancer. So there is possibility there. Now the most common side effects 30:00 are gastrointestinal. It’s nausea affects about 20 to 44% of patients 30:06 depending on the formulation with diarrhea, vomiting, constipation, abdominal pain, and also frequently 30:13 reported in clinical trials. I see this in my clinic, too, especially dose dependent. Um, and it happens early on 30:20 when you’re first starting the medication, but seems to settle out over time. The one that I would add to this 30:26 that I don’t think they have on here is an increase in acid reflux. We also see that quite often uh especially in people 30:33 who suffer with acid reflux to begin with. Now these effects are typically most 30:40 pronounced during the escalation and they like I said often improve over time 30:45 but more serious but less common adverse effects include acute pancreatitis. 30:51 The medication needs to be discontinued immediately if this is confirmed. You can see some diabetic retinopathy 30:57 complications in patients with pre-existing retinopathy and acute kidney injury. Um, this usually happens 31:05 secondarily to dehydration from the GI effects. There are some gallbladder disease um that can occur and people who 31:13 have a sensitive gallbladder will describe uh discomfort with that. I’ve 31:18 even seen some people who’ve had their gallbladder out on GLP1s at the higher doses complain of similar pain that they 31:25 used to have when their gallbladder was in. So, really important to just kind of monitor these symptoms and work closely 31:32 with somebody that understands them and can be on top of them quite quickly if this happens. Excuse me. From an 31:39 integrative medicine perspective, semiglutide really represents a powerful tool, but it’s not a standalone 31:46 solution. Remember, the medication addresses one aspect of the metabolic dysfunction, the signaling systems 31:53 controlling appetite and glucose homeostasis, but it doesn’t address the root cause that led to the metabolic 32:00 disease in the first place. Patients who rely solely on the medication without addressing the ultrarocessed food 32:07 consumption, the ccadian disruptions, the chronic stress, the sleep apnea, or 32:12 underlying hormonal imbalances often experience weight regain when the medication is discontinued. 32:20 The drug is also not a substitute for addressing the emotional and psychological drivers of eating 32:26 behavior, including the unresolved trauma that may manifest as emotional eating. I think this is really important 32:33 because we don’t address the trauma issue enough with clients and we need to 32:38 be looking at that. There is a huge trauma effect out there these days that is I don’t want to say leading to or 32:45 causing but it is definitely contributing to chronic illness and it’s not being talked about enough. So we 32:52 really need to be talking about this and addressing this trauma aspect. Now the next GLP that one that I want to talk 32:59 about is trespathide. This is a dual agonist. It takes center stage. It is my 33:05 favorite GLP one. Trisepatide is marketed as Mangjaro for type 2 diabetes 33:11 and Zepbound for chronic weight management and it represents the next 33:16 evolution in increantbased therapy. This is a dual agonist a 39 amino acid 33:23 synthetic peptide structurally based on the human glucose dependent insulin tropic peptide so GIP sequence but 33:31 modified to activate both the GIP receptors and the GLP1 receptors. So the 33:37 addition of the GI GIP agonism to the GLP1 agonism appears to create this 33:46 synergistic effect that goes beyond simply adding the two mechanisms together. So the GIP like GLP-1 is an 33:55 increant hormone secreted by what is called the K cells in response to nutrient intake. It enhances glucose 34:02 dependent insulin secretion but it also effects on atapost tissue metabolism 34:09 potentially improving the insulin sensitivity in fat cells and influencing 34:14 how the body stores and metabolizes fat. So some research suggests that GIP may 34:20 also have effects on energy expenditure though this remains an area of 34:26 investigation. So basically what we’re saying is this drug may actually help 34:32 people who are insulin resistant or insulin sensitive, not just somebody who 34:38 has problems with glucose control. So, this is super exciting because it opens 34:43 up the door for all of these people for decades that we’ve been trying to manage with insulin resistance and trying to 34:50 prevent diabetes and honestly most of the time have been unsuccessful 34:56 unless you can keep your diet at 50 grams of carbs or less a day, which is extremely difficult. Um, and take some 35:04 supplements that may or may not work and or take some metformin that may or may not help. this drug actually really 35:11opens that up and helps in that capacity. So there was a clinical trial 35:17 called the surmount clinical trial which demonstrated that trespathide produces 35:22 even more substantial weight loss than semiglutide. In the surerount one trial published by uh J tree I might have said 35:31 that wrong. I apologize if I slaughtered your name and colleagues in the New York England Journal of Medicine in 2022. 35:38 Participants receiving the highest dose of trespide, which is 15 milligrams, achieved an average weight loss of 20.9% 35:47 of their body weight over 72 weeks, compared to 3.1% with placebo. This 35:54 level of weight loss approaches what’s typically only seen in beriatric surgery. So, this is amazing because if 36:02 this medication works and we don’t have to do beriatric surgery, stomach stapling basically, um, oh my gosh, it’s 36:11 amazing. There are so many complications and risks that go with stomach stapling and the different procedures that they 36:17 do these days. People don’t absorb their nutrients properly. They have to do liquid nutrients. It’s very complicated. 36:24 It’s very challenging. Many of these people gain their weight back. Um, and 36:30 this procedure is not fun to go through. So, if we could change that and change 36:35 the lives of people who’ve really been struggling, it is amazing. And I will tell you that I have seen this work. I 36:42 have seen people lose 100 150 pounds on these medications over a year or two 36:50 period of time. It is definitely slower than beriatric surgery on some standpoints, but that is okay. You don’t 36:56 want that rapid weight loss. It’s not good for you. It’s not healthy for you. It doesn’t look well. You know, we want 37:03 to do this safely and effectively in the best way that we can possibly do that for you. Now, the adverse effect profile 37:10 is similar to semiglutide. It’s dominated by gastrointestinal effects. 37:15 Nausea, diarrhea, decreased appetite, vomiting, constipation. These were all commonly reported in the surmount 37:22 trials. And like semiglutide, tricepide carries a blackbox warning regarding the 37:27 thyroid sea cell tumors based on the rodent data and it shares the same contra indications in patients with a 37:34 family history of thyroid cancer and men too. So the mechanism behind why 37:40 tepatide often produces more substantial weight loss than GLP-1. The agonism 37:45 alone remains under investigation, but it may relate to the complimentary effects on the different aspects of 37:51 energy homeostasis or to GIP’s effects on atapost tissue and potentially on 37:58 central central nervous system pathways that GLP1 alone doesn’t fully address. 38:03 Now patients often report even more profound reductions in food noise with tricepide compared to GLP1 and uh sorry 38:12 GLP1 the agonists through this is anecdotal and hasn’t been regularly 38:17 quantified in quality studies. So I’ve done both uh personally and in my 38:22 practice. I really like trespide better than semiglutide. For me I had too many side effects with semiglutide. uh I had 38:30 less side effects with trespathide. I also plateaued on semiglutide which I 38:35 didn’t really care for. And with Tresepide, I haven’t plateaued and I’ve been able 38:42 to lose about 25 pounds in um a year and a half and I’ve been able to maintain 38:49 that. Um and I continued to use it because I do have a strong family history of cardiovascular disease. And 38:56 if this could help me so that I don’t follow my family lineage with cardiovascular disease, I am all for 39:03 trying to do that. I’ve watched too many of my family members suffer from this. I’ve lost my dad at a very young age. I 39:09 lost my grandfather at a young age to it. All of their brothers to this. And I don’t want to be that same person. So 39:16 that is why I chose to do that. And I think it’s really important for us to take a look at that and understand that. 39:24 Now, I know this has been a really long podcast and I don’t typically do podcasts this long. I have a whole host 39:31 of information on additional peptides. So, I’m going to break this up for you 39:36 guys and I’m going to do another episode and we’re going to pick up where we left off here with these peptides so that we 39:43 can actually start to dive into different peptides as well. So, check 39:48 out my next podcast show when we’re going to dive into the peptides that 39:54 talk about sexual wellness, immune function, and all the other cool things 39:59 that we can do with peptides. So until then, remember to like, share, and 40:04 subscribe. It really helps us get out to other people and share our information, 40:10 and join us for our next episode as we continue the talk about peptides. 40:15 Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and 40:21 information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its 40:28 management, or our partners. Each affiliate, sponsor, and partner is an 40:34 independent entity with its own perspectives. Today’s content is provided forformational and educational 40:40 purposes only and should not be considered specific advice, whether financial, medical, or legal. While we 40:48 strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique 40:56 circumstances. We encourage you to consult with a qualified professional to address your 41:01 individual needs. Your use of information from this broadcast is entirely at your own risk. By continuing 41:08 to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its 41:14 associates harmless from any claims or damages arising from the use of this 41:20 content. We may update this disclaimer at any time and changes will take effect 41:26 immediately upon posting or broadcast. Thank you for tuning in. We hope you 41:31 find this episode both insightful and thought-provoking. Listener discretion 41:36 is advised.The post Episode 256 – How Peptides Work, Benefits, and FDA-Approved vs Off-Label Use Explained first appeared on Let's Talk Wellness Now.

What is Pure Michigan actually built to do?Pure Michigan is not a “wake up and conquer the world” strain. It's usually a heavy hybrid that leans indica in feel, built more for depth than sparkle.This cultivar is commonly bred from Oreoz x Mendo Breath, which already tells you something. Both parents are known for dense structure, rich flavor, and body-forward effects.From Beehive Farmacy, batch specifics always matter, so check your label. But here's what Pure Michigan typically looks like chemically.• THC often in the high teens to mid 20 percent range• Very low CBD• Minor cannabinoids like CBG sometimes present in small amountsTranslation: this is THC dominant. If your tolerance is low, it can get heavy fast. This is not a microdose-first strain unless you intentionally keep it that way.Common dominant terpenes in Pure Michigan:• Caryophyllene• Myrcene• LimoneneCaryophyllene is the spicy, peppery terpene that also interacts with CB2 receptors, often associated with body relief.Myrcene leans sedating in higher concentrations.Limonene can add a slight mood lift or brightness.When myrcene and caryophyllene sit high together, you usually get that “deep exhale” body experience. Muscles loosen. Thoughts slow. The edges soften.Not guaranteed. But that's the tendency.At moderate doses:• Strong body relaxation• Slower mental pace• Warm, heavy calm• Possible couch gravityAt higher doses:• Sleep pressure• Brain fog• Hard pivot into “I'm done for the night”This is typically not a strain people use for high productivity. It leans evening. Recovery. Decompression.Who is this for:• People looking to wind down• Evening use• Body tension• High stress daysWho should be cautious:• Anyone sensitive to sedation• Anyone needing mental sharpness• New consumers jumping straight into large dosesThe real takeaway here is this: Pure Michigan is more about weight than sparkle. If you're chasing heavy body calm, it usually delivers. If you're chasing clarity and energy, this probably isn't your lane.And like we always say, strain names are branding. The batch chemistry is the truth. Always read the COA. Always start lower than you think.Utah cannabis makes more sense when you stop chasing names and start reading numbers.Keep the Mic on.Fuel the movement. Keep the conversation going.We keep a running list of tools and brands we personally enjoy and actually use.Find everything in one place here:

ABOUT THE EPISODEListen in to a special interview as COA's David Schrock and Stephen Wellum are joined by Steve Deace to talk about the best way to strategize and save lives, including a breakdown of the state of the Pro-Life and Abolitionist movements.Timestamps00:42 – Intro05:16 – How Do We Think About Incrementalism & Abolitionism? What is Most Effective?13:30 – What are Steps We Can Take to Disciple Zealous Brothers?22:17 – What is Recommended for Our Churches?26:57 – What Media is Most Effective in This Battle?30:50 – The Groundwork that Must Be Laid32:36 – What Would You Say for Pastors Who Consider This Too Political?36:27 – OutroResourcesThe Steve Deace ShowThe SBC's Turning Point (ft. Steve Deace) – Center For Baptist LeadershipTheme of the Month: Abolishing Abortion, Advocating for LifeGive to Support the Work

Accreditation can feel overwhelming, but when done well, it's not a once-every-ten-years scramble. Dr. Angie Mund joins us this week to help reframe accreditation as an ongoing leadership practice that shapes program culture, faculty development, and student outcomes. Drawing on decades of experience as a program director, department chair, and national leader, Dr. Mund explains what's usually true long before a successful COA site visit ever begins.  Here's some of what you'll hear in this episode:

Send Dr. Li a text here. Please leave your email address if you would like a reply, thanks.In this inspiring episode of the Make Time for Success podcast, host Dr. Christine Li welcomes back Megan Blacksmith, an NLP expert, speaker, and co-founder of Zesty. Together, they dive deep into visualization and neuro linguistic programming (NLP) as powerful tools for breaking old patterns, manifesting dreams, and achieving lasting inner transformation. Megan Blacksmith shares her story of accidental visualization, practical techniques for rewiring your mindset, and guidance on moving through resistance and limiting beliefs. You'll hear real-world examples and actionable strategies to help you create your ideal future—one that's possible, even if it feels out of reach today. Get ready to discover the secrets to manifesting your dreams with clarity, creativity, and confidence!Timestamps:00:00:00 - 00:02:47: Dr. Christine Li introduces the episode and welcomes Megan Blacksmith, who shares her expertise in NLP.00:02:48 - 00:05:35: Megan Blacksmith discusses her entry into NLP, its impact on her coaching, and how subconscious programming affects results.00:05:36 - 00:14:06: Exploration of how emotional events and hidden beliefs hold people back, including analogies like clutter.00:14:06 - 00:18:27: Discussing discomfort as a sign of growth and the challenges of stepping into a new identity.00:24:33 - 00:32:40: Insights into using visualization for goal achievement, with Megan Blacksmith's personal story as an example.00:32:41 - 00:39:00: Detailed visualization tips: make your vision vivid, specific, and emotionally charged.To sign up for the Waitlist for the Simply Productive Program, go to https://maketimeforsuccesspodcast.com/SPFor more information on the Make Time for Success podcast, visit: https://www.maketimeforsuccesspodcast.comGain Access to Dr. Christine Li's Free Resource Library -- 12 downloadable tools and templates to help you bypass the impulse to procrastinate: https://procrastinationcoach.mykajabi.com/freelibraryTo work with Dr. Li on a weekly basis in her coaching and accountability program, register for The Success Lab here: https://www.procrastinationcoach.com/labConnect with Us!Dr. Christine LiWebsite: https://www.procrastinationcoach.comFacebook Group: https://www.facebook.com/groups/procrastinationcoachInstagram: https://www.instagram.com/procrastinationcoach/TikTok: https://www.tiktok.com/@procrastinationcoachThe Success Lab: https://maketimeforsuccesspodcast.com/lab                       Simply Productive: https://maketimeforsuccesspodcast.com/SPMegan BlacksmithWebsite: http://www.becomingzesty.com/Podcast: http://becomingzesty.com/podcastInstagram: https://instagram.com/becomingzestyYouTube: https://www.youtube.com/@becoming_zesty

Pandemic Punch is that “turn the volume down on life” strain that still lets your brain stay online. First hit comes in bright and punchy, fruit and citrus up front, then it slides into a calm, floaty body ease that makes your shoulders drop without instantly stapling you to the couch. The vibe is happy, relaxed, and a little giggly, with a steady “I'm good” headspace.Smell and taste lean fruity-citrus with a skunky tang underneath, like sweet punch with a funky edge. It's the kind of profile that feels fun on the inhale, then settles into that mellow exhale where your body remembers it can unclench.Cannabinoids: THCA 26.291%, Total THC 23.269%, Total cannabinoids 27.137%, CBGA 0.561%, CBC 0.0739%, Δ9-THC 0.2115%, CBD and most minors ND.  Terpenes: β-Caryophyllene 0.689%, D-Limonene 0.352%, Linalool 0.342%, β-Myrcene 0.231%, α-Humulene 0.148%, everything else listed ND in this COA.  Best for: decompressing, pain-tension days, evening wind-down, and laughing at stuff that is not even that funny.Save on Dr Dabber with Code: Cannabisschool10Save on Storz & Bickel with Code : CannabisschoolSave on Santa Cruz Shredder with Code: CSP10Save on Bomb Erigs with Code: CSPScore 100 on your test

The Cheat Sheet is The Murder Sheet's segment breaking down weekly news and updates in some of the murder cases we cover. In this episode, we'll talk about cases from New Hampshire, New Jersey, Colorado, and Mississippi.NBC Boston's coverage of the murder of Judy Lord: https://www.nbcboston.com/news/local/nh-cold-case-unit-to-announce-significant-development-in-decades-old-case/3850076/CBS News's report on developments about Nazeer Hameed's involvement in the murders of Sasikala Narra and her son Anish Narra: https://www.cbsnews.com/philadelphia/news/sasikala-and-anish-narra-maple-shade-nj-cold-case/We also accessed news articles from the Concord Monitor, the Trenton Times, and the South Jersey Times via Newspapers.com.The ruling from the Colorado Court of Appeals on public access issues in the Edward R. Sandoval case about the murder of Dennis Lozoya: https://gazetteedit.wpenginepowered.com/wp-content/uploads/2025/11/22CA0824-Peo-v-Sandoval-10-30-25.pdfThe appeal filed in the case of William Ervin Edwards in the murder case of Robert Davis: https://courts.ms.gov/appellatecourts/docket/sendPDF.php?f=web0001.COA.2025-KA-138.118328.0.pdf&c=99062&a=N&s=2Find discounts for Murder Sheet listeners here: https://murdersheetpodcast.com/discountsCheck out our upcoming book events and get links to buy tickets here: https://murdersheetpodcast.com/eventsOrder our book on Delphi here: https://bookshop.org/p/books/shadow-of-the-bridge-the-delphi-murders-and-the-dark-side-of-the-american-heartland-aine-cain/21866881?ean=9781639369232Or here: https://www.simonandschuster.com/books/Shadow-of-the-Bridge/Aine-Cain/9781639369232Or here: https://www.amazon.com/Shadow-Bridge-Murders-American-Heartland/dp/1639369236Join our Patreon here! https://www.patreon.com/c/murdersheetSupport The Murder Sheet by buying a t-shirt here: https://www.murdersheetshop.com/Check out more inclusive sizing and t-shirt and merchandising options here: https://themurdersheet.dashery.com/Send tips to murdersheet@gmail.com.The Murder Sheet is a production of Mystery Sheet LLC.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Joint Readiness Training Center is pleased to present the one-hundredth-and-twenty-second episode to air on ‘The Crucible - The JRTC Experience.' Hosted by MAJ Marc Howle, the Brigade Senior Engineer / Protection Observer-Coach-Trainer, and MAJ David Pfaltzgraff, BDE XO OCT (formerly the BDE S-3 Operations OCT), from Brigade Command & Control (BDE HQ) on behalf of the Commander of Ops Group (COG). Today's guests are senior non-commissioned officers of JRTC: MSG Jared Cawthon, MSG Randell Conway, and SFC Corey Rinn. MSG Cawthon is the BDE Fires Support NCOIC and MSG Conway is the BDE Intelligence NCOIC OCT in Brigade Command & Control (BDE HQ). SFC Rinn is the Explosive Ordinance Disposal Senior OCT for TF-5 (BDE Engineer BN).   This episode focuses on leadership through the deliberate and effective utilization of Noncommissioned Officers at echelon, emphasizing that success in LSCO is fundamentally leader business, not officer business versus NCO business. A central theme is the NCO's role in identifying and mitigating friction before it manifests in execution. Drawing on repeated JRTC observations, the discussion highlights how experienced NCOs sharpen plans through rehearsals, checklists, and anticipation of second- and third-order effects—time, distance, sustainment, displacement, and execution risk—that are often missed in rushed or staff-centric planning. When NCOs are fully integrated into MDMP, mission analysis, COA development, and rehearsals, staffs are more synchronized, plans are more executable, and formations adapt faster once friction is encountered.    The episode also addresses persistent gaps in how formations employ NCOs, particularly on staffs. Too often, senior NCOs are relegated to security or administrative tasks instead of being empowered contributors to planning, targeting, and cross–warfighting function integration. The panel underscores disciplined initiative, delegation of authority, and clear roles and responsibilities as decisive leadership practices that unlock NCO potential. Effective formations deliberately train NCOs to operate confidently in planning environments, leverage their experience to challenge assumptions, and serve as connective tissue between operations, intelligence, fires, sustainment, and protection. The consistent takeaway is clear: units that empower NCOs as planners, synchronizers, and leaders—not just executors—operate with less friction, greater cohesion, and higher combat effectiveness in the hardest fights.    Part of S13 “Hip Pocket Training” series.   For additional information and insights from this episode, please check-out our Instagram page @the_jrtc_crucible_podcast   Be sure to follow us on social media to keep up with the latest warfighting TTPs learned through the crucible that is the Joint Readiness Training Center.   Follow us by going to: https://linktr.ee/jrtc and then selecting your preferred podcast format.   Again, we'd like to thank our guests for participating. Don't forget to like, subscribe, and review us wherever you listen or watch your podcasts — and be sure to stay tuned for more in the near future.   “The Crucible – The JRTC Experience” is a product of the Joint Readiness Training Center.

Friend, we obsess over steps, macros, and workout streaks… but when was the last time you checked in on your emotional fitness? In this episode, Nicole sits down with clinical psychologist, emotional fitness expert, and Coa co-founder Dr. Emily Anhalt to talk about what it actually looks like to “train your brain” — no toxic positivity, no “just meditate more,” and definitely no pretending everything's fine when it's very much not.  Emily breaks down her 7 traits of emotional fitness (think mindfulness, curiosity, boundaries, resilience, empathy, communication, and play) and how to build them like muscles over time — one emotional push-up at a time. We get into why empathy without boundaries will burn you all the way out, how to ask for feedback without spiraling into defensiveness, and why trusting your future self might be the most confidence-building thing you do this year.  If you've ever felt resentful because you said “yes” when every cell in your body wanted to say “no,” if you're tired of carrying everyone else's emotions like luggage, or if anxiety and uncertainty have been driving the bus lately, this one's for you. Emotional fitness won't stop life from throwing heavy shit your way — but it will make you strong enough to carry it, move it, and eventually put it down. We explore: What emotional fitness actually means (and how it's different from “fixing yourself”) The 7 traits of emotional fitness — and why you don't have to master all of them at once How to spot the cost of avoiding discomfort (hello, resentment and burnout)The “emotional push-up” exercise you can start doing today How to hold empathy and boundaries so caring for others doesn't drain you dry The best advice Emily ever got for dealing with anxiety and uncertainty Why trusting your future self is a deeply confident way to live Because when you trust your future self, you stop living in panic about what might happen and start living with confidence in who you're becoming — and that shifts everything.  Thank you to our sponsors! Get 20% off your first order at curehydration.com/WOMANSWORK with code WOMANSWORK — and if you get a post-purchase survey, mention you heard about Cure here to help support the show!  Sex is a skill. Beducated is where you learn it. Visit https://beducate.me/pd2550-womanswork and use code womanswork for 50% off the annual pass. Connect with Emily: Website: https://www.dremilyanhalt.com/ Book: https://a.co/d/couFOLN IG: https://www.instagram.com/dremilyanhalt/ X: https://x.com/dremilyanhalt LI: https://www.linkedin.com/in/dremilyanhalt/ Related Podcast Episodes Your Brain Is a Filthy Liar with Bizzie Gold | 361 How To Play: Shift Your Thinking, Inspire Connection & Spark Creativity with Cas Holman | 355 144 / Jay & Nicole Kalil on Partnership, With Guest Host Lynn Casaletto Share the Love: If you found this episode insightful, please share it with a friend, tag us on social media, and leave a review on your favorite podcast platform!

This week, I talk with Dr. Emily Anhalt—a clinical psychologist, founder, and writer who's spent the past 15 years exploring what it really means to be emotionally healthy. You might know her from her TED Talk or her work at Coa, but in this conversation, we go deeper. We talk about growing up in Silicon Valley, the pressure of being a high-achieving kid, and why so many successful people still carry unresolved grief. Emily shares how ADHD shaped her early life, what led her to leave pre-med for psychology, and how emotional patterns from childhood often resurface in our work and relationships. We also dive into what actually makes therapy effective and why hitting your goals doesn't always bring peace. If you've ever built something meaningful but still felt unsettled, or questioned what's really driving your ambition, I think this episode will speak to you. Let's get to it. In this episode: (00:00) - Intro (02:52) - How a beanbag chair and snacks helped Emily unlock her best work (08:01) - Growing up inside the Silicon Valley success machine (09:45) - Why high performers need a different kind of therapy  (11:53) - The story of Emily's parents and how they ended up in the Valley (13:54) - Reframing ADHD as a strength, not a stigma (16:33) - The early experiences that shaped Emily's emotional lens (23:40) - How Emily chose psychology—and what kept her going (28:40) - The moment therapy stopped being about symptoms (33:06) - Why grief is a necessary companion to growth (38:21) - The origin story of a company built around emotional fitness (42:30) - What changes when you go from therapist to founder (45:27) - The qualities of high-integrity therapy (51:26) - How Emily knew it was time to write a book (58:20) - What really keeps entrepreneurs stuck—and how to get unstuck (01:02:09) - What it feels like when success leaves you empty (01:05:32) - How to rebuild when your goals stop making sense (01:07:44) - Why achieving meaning isn't the same as feeling it (01:11:06) - Why therapy often gets harder before it gets better (01:12:47) - Abandoning hard feelings before healing happens (01:13:40) - The isolation of success—and how to find support (01:21:17) - How overachievers get trapped in burnout (01:29:26) - Healthy ways to process anger (01:33:46) - What makes Emily world-class? (01:34:09) - Emily's most beautiful future (01:34:49) - Who Emily is becoming Get full show notes and links at https://GoodWorkShow.com.Watch the episode on YouTube: https://www.youtube.com/@barrettabrooks.